Clinical Digest: Recent Clinical Trials on Influenza (2026-04)
To assist researchers and healthcare practitioners in staying up-to-date with the latest advancements in clinical research, the Clinical Digest Team has compiled a comprehensive list of recent clinical trials related to Influenza. These trials are organized by their release dates for your convenience. (Last updated on: 2026-04-06)
This curated list is brought to you by the Clinical Digest Team. Experience the cutting-edge capabilities of Clinical Digest, an innovative AI-powered clinical research platform that gets you the personalized and comprehensive updates on the latest clinical research in your field. It also empowers you to read articles, write articles, conduct literature reviews and generate research reports.
Experience the full potential of our services today!
TABLE 1: Clinical Digest: Recent Clinical Trials on Influenza (2026-04)
| Clinical Trial | Contact(s) | Updated | |
|---|---|---|---|
| 1 | SAVE: School Ambassadors for Vaccine Education PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Influenza is associated with millions of cases of school absenteeism due to illness, hundreds of hospitalizations and thousands of deaths in the U.S. each year, which can be greatly reduced with influenza vaccination. The goal of this randomized controlled trial is to learn if training school personnel in vaccine communication techniques and equipping schools with vaccine promotional materials targeting students and their parents/guardians increases the influenza vaccination rates of the student population within participating schools. The main question it aims to answer is: -Will flu vaccination rates be higher in intervention schools compared to control schools by the end of the intervention period? Participating schools will: * Have select school personnel (school nurses, coaches, teachers, etc.) complete an online training module and optional training workshop focused on vaccine communication \[intervention arm only\] * Utilize vaccine promotional materials (posters, flyers, digital files for social media, etc.) provided by the study team during flu season \[intervention arm only\] * Track student vaccination rates \[intervention + control arm\] |
CYNTHIA RAND; | 2026-03-05 |
| 2 | A Prospective Cohort Study To Compare The Burden Of Medically Attended and Community RSV, HMPV, SARS-CoV-2 and Influenza LRTI In Infants And Children Under 5 Years Of Age and Adults (16-60 Years) In Rural India PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Trial Title: A Prospective Cohort Study To Compare The Burden Of Medically Attended and Community LRTI In Infants And Children Under 5 Years Of Age and adults (16-60 years) In India Primary Objectives: * To determine the population-based epidemiology, clinical features, and mortality of respiratory syncytial virus (RSV) lower respiratory tract illness (LRTI) in infants, children under 5, and adults (16-60 years) in rural India. * To calculate the incidence of RSV LRTI classifications (non-severe, severe, very severe, hospitalization, and mortality) per 1,000 child/adult years of observation. Secondary Objectives: • To determine the population-based epidemiology of human metapneumovirus (hMPV), SARS-CoV-2, … |
ASHISH R SATAV; | 2026-02-18 |
| 3 | Viromes in Infants Presenting With A Septic Syndrome PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Fever in infants younger than 3 months is a common reason for emergency department visits and is associated with a significant risk of serious bacterial infections. Because it is difficult to distinguish bacterial from viral infections at presentation, management is often aggressive and includes invasive procedures, hospitalization, and empiric antibiotic therapy. Despite advances in molecular diagnostics, the etiology of fever remains unidentified in a substantial proportion of cases. This study aims to assess the presence of pathogenic viruses in respiratory and intestinal samples from febrile infants younger than 3 months compared with afebrile controls, and to explore associations with clinical, … |
UNIVERSITY HOSPITAL MONTPELLIER | 2026-03-17 |
| 4 | Effect of Methotrexate Discontinuation on Immunogenicity of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Patients With Autoimmune Rheumatic Diseases PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial aims to evaluate the effect of temporary methotrexate (MTX) discontinuation on the humoral immunogenicity of the 20-valent pneumococcal conjugate vaccine (PCV20) in adult patients with autoimmune rheumatic diseases (ARDs). Key questions: * Does suspending MTX for 2 weeks after PCV20 enhance humoral immunogenicity? * What is the impact of MTX discontinuation on functional opsonophagocytic activity (OPA) and cellular immunity? * What is the risk of disease flaring with MTX withdrawal? |
UNIVERSITY OF SAO PAULO GENERAL HOSPITAL | 2026-03-24 |
| 5 | A Phase 3, Randomized, Observer-blind, Placebo-controlled Study to Evaluate The Immunogenicity, Safety, and Reactogenicity of MRNA-1018-H5 Pandemic Influenza Vaccine in Adults ≥18 Years of Age PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age. |
MODERNATX | 2026-04-03 |
| 6 | Examining The Effectiveness of Single-Limb Exercise Training for COPD Patients During Exacerbation Periods PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Resistance exercise applications during acute exacerbations of Chronic Obstructive Pulmonary Disease (COPD) are employed to enhance functional capacity and prevent muscle atrophy by increasing muscle strength. Owing to the limited cardiorespiratory reserve of COPD patients, … |
ALPER KEMAL GÜRBÜZ; | 2026-01-16 |
| 7 | The Disease Burden of RSV Infection in Hong Kong PF:8 Related Papers Related Patents Related Grants Related Experts Highlight: RSV infection causes significant mortality and morbidity in susceptible adults. There are many publications on the global RSV disease burden in infants and young children but data on adults are lacking with lots of knowledge gaps. Currently there is no established effective antiviral therapy for RSV. RSV vaccines have recently become available commercially but the Center for Health Protection (Hong Kong) has yet to discuss procurement of RSV vaccines for the high risk groups. Thus a prospective study to assess the disease burden of RSV infection in adults would be of great interest. |
KA PANG CHAN; | 2026-01-08 |
| 8 | Clinical Assessment of Respiratory Events for Kids: Integrating Diagnostics and Stewardship PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study, called Care4Kids, aims to improve the management of respiratory infections in children visiting emergency departments. The research will evaluate the impact of using the BIOFIRE® SPOTFIRE® R/ST Panel, a rapid molecular point-of-care test, compared to standard care. Children aged 2 months to 18 years with symptoms of respiratory tract infection or flu-like illness will be enrolled. After consent, … |
BIOMÉRIEUX | 2026-03-06 |
| 9 | Effect of Oral Supplement Intervention on Influenza Vaccine Long-term Efficacy: A Follow-up Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a follow-up study of a previously completed randomized controlled trial (NCT06827873) that investigated the effects of oral supplements on influenza vaccine response in adults aged 60-70 years. The original study was completed in April 2025, with participants receiving either TUDCA (Tauro Ursodesoxy Cholic Acid) supplementation, fatty acid supplementation, or placebo during influenza vaccination. The primary objectives of this follow-up study are to: 1. Evaluate the durability of vaccine-induced antibody responses approximately 8 months post-vaccination 2. Assess the persistence of immune memory cells, … |
AI ZHAO; | 2026-01-22 |
| 10 | A Randomized, Observer-Blind, Adaptive, Active Comparator-Controlled, Dose-Ranging, Multicenter, Safety, Tolerability, and Immunogenicity Phase 1/2 Study of A Plant-Based Seasonal Recombinant Trivalent VLP Influenza Vaccine in Adults 18 Years of Age and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This Phase 1/2 study is intended to assess the safety, tolerability, and immunogenicity of recombinant TVLP in adults 18-64 and 65 years of age and above and to confirm the dose(s) to be developed further in these two age cohorts. |
ARAMIS BIOTECHNOLOGIES | 2026-03-13 |
| 11 | A PHASE 2, RANDOMIZED, DOUBLE-BLIND, CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MRNA VACCINES AGAINST INFLUENZA IN ADULTS 18 YEARS OF AGE AND OLDER PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about safety in participants taking the study vaccine (mRNA-based vaccine) and the ability of the study vaccine to trigger the body’s immune response, targeting the flu virus (influenza virus). This study is seeking healthy participants 18 years of age or older. All participants in this study will receive only 1 dose in their arm, to deliver one of the experimental flu vaccines or one of the approved flu vaccines used for comparison. Participants will take part in this study for about 6 months, … |
PFIZER | 2026-03-20 |
| 12 | Human Factors and Clinical Validation of The CorDx Tyfast Flu A/B & COVID-19 At Home Multiplex Rapid Test Using Anterior Nares Nasal Samples for Over-The-Counter (OTC) Use PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The study’s primary objective is to evaluate the performance of the CorDx Tyfast Flu A/B \& COVID-19 At-Home Test for detecting SARS-CoV-2, Influenza A, and B in nasal samples collected by lay users, compared to 510(k)-cleared RT-PCR tests. Secondary objectives are to assess usability and instruction comprehension and reproducibility with untrained operators at Clinical Laboratory Improvement Amendments (CLIA)-waived sites. |
CORDX | 2026-02-24 |
| 13 | A Single-Center, Randomized, Blinded Phase I Clinical Trial to Evaluate The Safety and Immunogenicity of Influenza Virus Vaccine (BK-01 Adjuvant) in Populations Aged 18 Years and Older PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the safety and immunogenicity of the influenza virus vaccine (BK-01 adjuvant) in people aged 18 years and older. The main questions it aims to answer is: • Incidence rate of adverse reactions/events after administration Participants will be randomly vaccinated with a single dose of the trial vaccine, control vaccine, adjuvant placebo, or placebo in a 1:1:1:1 ratio. After vaccination, all participants will undergo up to 30-day observation and blood collection. |
CHANGCHUN BCHT BIOTECHNOLOGY | 2026-01-16 |
| 14 | Effect of A Goat-milk Based Infant Formula on Gastrointestinal Symptoms and Tolerability in Healthy Term Infants: A Double-blind Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow’s milk formula on gastrointestinal symptoms and tolerance, and infections in infants. |
AUSNUTRIA HYPROCA B V | 2026-01-15 |
| 15 | Investigation of The Effects of Oxidized Antigens on The T-Cell Response and The Epigenetic Reprogramming of Neutrophils in Lung Diseases – OXIGENE – PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses. |
JAN HEYCKENDORF; | 2026-02-04 |
| 16 | VDJ-recombination of The B-cell Receptor Following Hematopoietic Stem Cell Transplantation, An Observational Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: When a person undergoes a stem cell transplant-an important procedure used to treat serious blood diseases such as leukaemia, lymphoma, or myeloma-the entire immune system is affected. The transplant essentially resets the immune system, meaning that the patient loses much of the protection against infections that has been built up over a lifetime. After the transplant, the patient therefore needs to be revaccinated against several diseases, such as tetanus, diphtheria, polio, COVID-19, and pneumococcal disease. In this study, … |
UMEÅ UNIVERSITY | 2026-01-16 |
| 17 | A Double-blinded, Phase 1 Clinical Trial to Establish An RG-A/Texas/71/2017 (H3N2) Influenza Controlled Human Infection Model (CHIM) That Safely and Reproducibly Induces Symptomatic Influenza Virus Infection in Healthy Adults 18-45 Years of Age After Intranasal Challenge PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The overall objective is to establish an influenza Controlled Human Infection Model (CHIM) in Canada that can be used to assess the safety and efficacy of candidate vaccines, biologics, and therapeutics targeting influenza viruses. |
DALHOUSIE UNIVERSITY | 2025-12-26 |
| 18 | The Impact of Live Attenuated Intranasal Influenza Vaccine Exposure on Mucosal Immunity PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The research of the investigators is focused on the understanding how the immune system functions and responds to intranasal vaccines. Intranasal vaccines do not lead to the same changes in the blood that intramuscular vaccines do. Therefore, … |
ADAM KAUFMAN; | 2025-12-19 |
| 19 | Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia at Phu Tho Provincial Obstetrics and Pediatrics Hospitals Within 2026-2027 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The main questions this study aims to answer are: * Does using probiotic nasal spray (LiveSpo Navax containing Bacillus subtilis and Bacillus clausii, 1×10\^9 CFU/mL), with or without oral probiotics (LiveSpo Pregmom containing Bacillus subtilis, Bacillus clausii, and Bacillus coagulans, 3×10\^9 CFU/5 mL), … |
LOC V NGUYEN; | 2026-02-10 |
| 20 | Assessment of Functional Impact of Acute Respiratory Viral Infections in Older Adults – An International Multi-center Study PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The prevention of infectious diseases in older adults remains a major public health challenge, as acute respiratory infections are a leading cause of hospitalisation, mortality, and functional decline worldwide. Immunosenescence and environmental exposures increase susceptibility to infection and reduce vaccine effectiveness in this population. Respiratory viruses, including influenza, SARS-CoV-2, respiratory syncytial virus, and human metapneumovirus, account for a substantial share of this burden, much of which is vaccine-preventable. However, … |
UNIVERSITY HOSPITAL GRENOBLE | 2026-02-04 |
| 21 | An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Influenza Community-Acquired Pneumonia in Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Severe community-acquired pneumonia caused by influenza virus (hereafter referred to as severe influenza pneumonia) is a major etiology of community-acquired pneumonia leading to acute respiratory failure and ICU admission. It can rapidly progress to profound hypoxemia, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction, and remains associated with substantial mortality. Although antiviral therapy-typically neuraminidase inhibitors-and well-established organ-support strategies are currently available, outcomes in a subset of critically ill patients remain poor despite antiviral and supportive care alone, with ICU mortality reported to be as high as 20-30%. Therefore, … |
QINGYUAN ZHAN; | 2026-01-20 |
| 22 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate The Safety, Tolerability, and Immunogenicity of VAX-31 Concomitantly Administered With Seasonal Influenza Vaccine in Healthy Subjects 50 Years of Age and Older PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This is a Phase 3, randomized, double-blind study to evaluate the safety and immunogenicity of VAX-31 and seasonal influenza vaccine in pneumococcal-naïve adults ≥ 50 years when the two vaccines are administered at the same visit or separately. |
VAXCYTE | 2026-03-31 |
| 23 | Study Evaluating The Impact of Using Triplex Rapid Diagnostic Tests (SARS-CoV-2/Influenza/RSV) on Antibiotic Prescribing in The General Population in Community Settings PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: Respiratory infections are very common, especially during winter, and are often caused by viruses such as influenza, SARS-CoV-2 or respiratory syncytial virus (RSV). These illnesses are generally mild, but their symptoms do not always allow a clear distinction to be made between a viral infection and a bacterial infection. In the absence of a precise diagnosis, antibiotics may be prescribed when they are not necessary in many cases. However, the excessive use of antibiotics contributes to the development of bacterial resistance, … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2026-01-14 |
| 24 | A Randomized, Double-blind, Active-controlled Phase Ⅱ Clinical Trial to Evaluate The Immunogenicity and Safety of The Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above. |
SHANGHAI INSTITUTE OF BIOLOGICAL PRODUCTS | 2026-01-15 |
| 25 | ORegon CHild Absenteeism Due to Respiratory Disease Study – Air Surveillance PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this observational study is to compare the effectiveness of air surveillance and to better understand the relationship between household transmission and viruses detected in the air. Participants will provide nasal swabs and have an air sample surveillance device installed in their home. |
JONATHAN TEMTE; | 2026-01-22 |
| 26 | Volatile Organic Compounds Analysis for Rapid Testing Using EXhaled Breath for Respiratory Infection PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: Emerging respiratory diseases are a global health threat. Viruses such as influenza and coronaviruses have been the main cause of pandemics over the last century. In general, the impact of these respiratory infections is not limited to pandemic risks. Indeed, some pathogens also induce seasonal epidemics with a significant medical and economic burden. It is therefore essential to strengthen global surveillance, warning systems and early diagnosis capabilities for pathogens responsible for respiratory infections. One promising and recognized approach is the analysis of exhaled air, which contains a complex mixture of volatile organic compounds (VOCs), … |
ALEXANDRE GAYMARD; | 2026-01-16 |
| 27 | Volatile Organic Compounds Analysis for Rapid Testing Using EXhaled Breath for Respiratory Infection in Hospitalised Patients PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Emerging respiratory diseases represent a global threat. Viruses such as influenza and coronaviruses have been the main drivers of pandemics over the past century. More broadly, the impact of these respiratory infections is not limited to pandemic risks. Indeed, some of them also trigger seasonal epidemics with a significant medical and economic burden. Consequently, it is essential to strengthen global surveillance, and diagnostic capacities for the pathogens responsible for respiratory infections. The diagnosis of respiratory infections is even more important in cases of severe infection, … |
HOSPICES CIVILS DE LYON | 2026-01-20 |
| 28 | EMIT-2b: Evaluating Modes of Influenza Transmission Through The Conduct of Controlled Human Influenza Virus Infection Transmission Trials (CHIVITTs) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a research study to investigate how influenza transmits from person-to-person. Participation as a healthy Recipient in this study involves: * Home semi-quarantine lasting about 14 days during which the participants must wear an N95 in class and take other precautions * Daily assessments and clinic visits for 14 days * Spending every weekday evening for about 14 days from around 6 – 10 pm, including a provided dinner, … |
DONALD K. MILTON; | 2026-01-15 |
| 29 | Seroconversion Following RSV Vaccination in Bone Marrow Transplant and CAR-T Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study evaluates whether the RSV vaccine Abrysvo can produce an antibody response in patients with blood cancers who have previously received a hematopoietic stem cell transplant (HSCT) or CAR-T cell therapy. The vaccine targets the prefusion F (preF) protein of RSV, which is an important component of protective immunity against the virus. The main goal of the study is to measure the change in antibody levels against the preF protein four weeks after vaccination compared with levels before vaccination. The study will also assess whether participants develop a meaningful immune response, … |
ANIL RENGAN; | 2025-12-22 |
| 30 | Impact Evaluation of A Prescription Search Support (PSS) for Antimicrobials Using A Stepped-Wedge Cluster Randomized Design in Belgian Primary Care PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Inappropriate antibiotic prescribing in primary care remains an important contributor to antimicrobial resistance. Despite the availability of evidence-based clinical guidelines, antibiotics are still frequently prescribed for self-limiting infections. Digital clinical decision support tools may help general practitioners (GPs) align prescribing decisions with guideline recommendations during patient consultations. This study evaluates the impact of a digital Prescription Support System (PSS) designed to support antimicrobial prescribing in Belgian primary care. The PSS provides guideline-based recommendations derived from the Belgian BAPCOC guidelines for common infections in ambulatory care. Recommendations are presented through a user-friendly decision tree that is integrated into existing electronic health record systems and can be consulted during routine care. The study is embedded within the national implementation strategy of the PSS coordinated by the National Institute for Health and Disability Insurance (RIZIV-INAMI). A stepped-wedge cluster randomized design is used, in which participating general practices transition sequentially from usual care to access to the PSS over four predefined implementation steps. This approach ensures that all participating practices eventually receive access to the system while allowing comparisons over time. The primary objective is to assess whether implementation of the PSS is associated with changes in antibiotic prescribing in Belgian general practice. Prescribing outcomes are measured using routinely collected indicators from the Belgian Antibiotic Barometer, including overall antibiotic prescribing rates and the use of broad- versus narrow-spectrum antibiotics. Secondary objectives include assessing the usability and acceptability of the PSS among clinicians and identifying factors that influence its adoption in daily practice. The study will also monitor potential unintended consequences, such as changes in workflow or concerns about underprescribing. Findings from this study will inform future decisions regarding further optimization and wider implementation of the PSS in Belgian primary care. |
JAN VERBAKEL; | 2026-03-06 |
| 31 | Effectiveness of Cod-Derived Omega Oil Enriched With Free Fatty Acids Against The Common Cold and Other Respiratory Infections in Healthy Icelandic Adults During The Influenza Season PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to investigate whether fish oil containing free fatty acids affects people’s susceptibility to viral infections such as colds, influenza, and COVID-19, as well as the course of these illnesses. Omega Cold is purified fish oil with 2% added free fatty acids, … |
MAGNUS GOTTFREDSSON; | 2026-01-02 |
| 32 | A Randomized, Double-blind, Controlled Phase I Clinical Trial to Evaluate The Safety and Immunogenicity of The Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, blinded, controlled phase I clinical trial with a total of 120 participants aged ≥ 60 years. Experimental group: Influenza virus split vaccine (0.7mL/vial), control group 1: Influenza virus split vaccine, control group 2: placebo group. The three groups were recruited at a ratio of 1:1:1, and 40 individuals were randomly vaccinated in each group. Each person was injected with one dose of the vaccine into the deltoid muscle of the upper arm. Participants in each study group are required to undergo laboratory indicator tests before and on the 4th day after vaccination. |
YEQING TONG; | 2026-01-14 |
| 33 | A Multicenter, Open-Label, Randomized Phase 2a Study to Evaluate The Safety and Efficacy of Different Oral Doses of TRX-100 and Standard of Care in Participants With Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an early-stage clinical trial to determine a safe and effective dose for Tivoxavir Marboxil (TRX-100) in patients with mild to moderate Influenza. Participants will take a study drug as well as a standard therapy. A descriptive statistics will be used to present the study results. |
TRAWS PHARMA | 2026-03-27 |
| 34 | Impact of Influenza Vaccination on Nasal Resident Memory Immune Responses and Peripheral Respiratory-tropic Memory Immune Responses PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Mucosal sites, such as respiratory mucosa, are the primary entry points entry points for pathogens. However, clinical evaluation of vaccines against respiratory respiratory pathogens is currently based primarily on analysis of systemic, i.e. peripheral antibody and cellular responses. These measurements give little indication of the immune responses in respiratory tissues tissues, even though the latter are essential for protection against infection. Protective immune responses in mucous membranes, including respiratory including respiratory tissues, rely on secretory IgA to neutralize pathogens neutralization of pathogens on the mucosal surface, as well as the development of the development of cellular responses, … |
ELISABETH BOTELHO-NEVERS; | 2025-12-30 |
| 35 | Comparison of Immunogenicity of Different Influenza Vaccines in Patients With Hematologic Malignancies PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized controlled trial evaluates and compares the immunogenicity of three different influenza vaccine formulations: high-dose trivalent (HD-IIV3), MF59-adjuvanted quadrivalent (aIIV4), and standard-dose trivalent (SD-IIV3) vaccines. The study population consists of patients with hematologic malignancies, including those undergoing autologous stem cell transplantation or CAR-T cell therapy. The primary goal is to identify which vaccine strategy elicits the most robust antibody and T cell-mediated immune responses in this severely immunocompromised population |
SUNG-HAN KIM; | 2026-03-24 |
| 36 | Influenza Vaccination After Acute Coronary Syndrome PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if influenza vaccination can prevent adverse cardiac events in Chinese acute coronary syndrome patients. The main questions it aims to answer are: * Whether influenza vaccination can decrease events of cardiovascular death, MI, or stroke? * Whether influenza vaccination can decrease events of all cause death, unplanned revascularization, unplanned hospitalization for heart failure or for arrhythmia, … |
DAO WEN WANG; | 2026-01-13 |
| 37 | Unveiling The Fungal Frontier: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance. |
ASMAA NADY HUSSEIN; | 2025-08-14 |
| 38 | Post-Exposure Influenza Chemoprophylaxis With Oseltamivir for Five Days Vs Ten Days in Acute-Care Hospital: A Non-Inferiority Randomized Open-Label Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza in a hospital setting. |
DAŠA STUPICA; | 2026-04-01 |
| 39 | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate The Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Onradivir Tablets in participants aged 12 to 17 years with influenza A virus infection. The trial plans to enroll approximately 150 adolescent participants (12-17 years) with uncomplicated influenza A, confirmed by rapid antigen/nucleic acid testing and within 48 hours of symptom onset. Eligible participants who meet the inclusion criteria and do not meet any exclusion criteria will be randomized in a 2:1 ratio to receive either Onradivir Tablets or placebo once daily for 5 consecutive days. The study consists of a screening period, a treatment period, … |
RUIJIN HOSPITAL | 2025-11-17 |
| 40 | Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under A Hospital-based Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the efficacy of antiviral prophylaxis in preventing in-hospital influenza transmission. We will enroll hospitalized patients with confirmed influenza (index cases) and their uninfected roommates (room contacts). These room contacts will be randomized in a 1:1:1 ratio to one of three prophylactic groups: placebo, suraxavir marboxil, or oseltamivir. The primary outcome will be the rate of influenza infection among the room contacts, which will be monitored to determine the effectiveness of the interventions. |
BIN CAO; | 2026-03-23 |
| 41 | A Phase 3 Study of ZSP1273 in Otherwise Healthy Children 2-11 Years Old With Influenza A PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This trial is conducted in China. The aim of the trial is to investigate safety and efficacy of ZSP1273 granules |
GUANGDONG RAYNOVENT BIOTECH | 2025-12-16 |
| 42 | A Randomized, Blinded, Controlled Phase I Clinical Trial to Evaluate The Safety of A Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Adults Aged 65 Years and Older PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study was to evaluate the safety of quadrivalent subunit influenza vaccine (adjuvant) in people aged 65 years and older. |
YEQING TONG; | 2026-02-19 |
| 43 | A Randomized, Blinded, Controlled Phase I Clinical Trial to Evaluate The Safety of A Subunit Influenza Vaccine (Adjuvant) in Adults Aged 65 Years and Older PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study was to evaluate the safety of subunit influenza vaccine (adjuvant) in people aged 65 years and older. |
YEQING TONG; | 2026-02-19 |
| 44 | IDCRP-154: Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine. |
EDWARD MITRE; | 2025-12-17 |
| 45 | A Phase 1, Double-blind, Randomized Trial to Evaluate Safety and Immunogenicity of Fluzone® High-Dose Influenza Vaccine When Concomitantly Administered With CD388, A Novel Long-Acting Antiviral Conjugate for The Prevention of Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical study is to investigate how safe and effective it is to receive both the Fluzone® High-Dose (HD) influenza vaccine and CD388, a long-acting antiviral medicine, at the same time. Some participants will receive the vaccine and CD388, while others will receive the vaccine and a placebo. The study aims to determine whether taking CD388 together with the flu vaccine affects the body’s ability to build protection-called an immune response-against the flu, … |
CIDARA THERAPEUTICS | 2026-03-24 |
| 46 | A Randomized, Double-blind Phase III Clinical Study of ZSP1273 Tablets Compared With Placebo in Children 12-17 Years Old With Acute Uncomplicated Influenza A PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This trial is conducted in China. This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to assess the efficacy and safety of ZSP1273 in the treatment of Acute Uncomplicated influenza A in adolescents. |
GUANGDONG RAYNOVENT BIOTECH | 2025-12-16 |
| 47 | A Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Phase III Clinical Study Evaluating The Safety, Pharmacokinetics, and Efficacy of JKN2301 Dry Suspension in Pediatric Patients Aged 2 to Under 12 Years With Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this phase III study is to learn if JKN2301 Dry Suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years. |
JOINCARE PHARMACEUTICAL GROUP INDUSTRY | 2026-01-21 |
| 48 | Vaccination Nudges Project: Behavioural Nudges From Pharmacists to Increase Influenza and Travel Vaccination Uptake: A Pragmatic Randomized Control Trial PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this individual-level pragmatic randomized policy trial is to learn about the impact of behavioural nudges via mailed letters on increasing influenza and travel vaccination uptake in Alberta, Canada. The primary outcome is the proportion of adults receiving influenza and/or travel vaccination. The secondary outcome is the number of stroke events in the 6 months following vaccination. As such, this research aims to answer two key questions: 1. Do behavioural nudges increase influenza and travel vaccination in Alberta? 2. If yes, … |
AMITY QUINN; | 2026-02-10 |
| 49 | Definition of Sub-phenotypes of Pneumonia Based on The Respiratory Microbiome Composition to Predict Microbial and Clinical Treatment Failures PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Pneumonia remains a leading cause of antibiotic consumption globally, contributing significantly to the burden of antimicrobial resistance (AMR). The respiratory microbiome plays a crucial role in the emergence of AMR and therapeutic failure in both community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP). The PHENOMENON study aims to investigate the relationship between the respiratory microbiome composition and clinical outcomes to improve the prediction of treatment failure and AMR emergence. Methods: This multicenter prospective cohort study will include 300 adult patients across three cohorts: CAP in general wards, severe CAP in intensive care units (ICU), … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2025-11-24 |
| 50 | Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial): Safety and Immunogenicity of Pandemic Influenza Vaccine in Organ Transplant Recipients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the next influenza pandemic may be soon approaching. Transplant patients will likely be uniquely predisposed to serious infection with high morbidity and mortality. There are a number of important reasons that evaluation of prevention strategies are critical in this highly vulnerable population. Currently, … |
VICTORIA HALL; | 2025-12-18 |
| 51 | Clinical Validation of The Aptitude Medical Systems Metrix Respiratory Panel Test in At-Home/Non-Laboratory Settings PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The Metrix Respiratory Panel Test will be evaluated for use in Non-Laboratory settings in a home testing environment utilizing the clinical study design described herein. The study will take place in simulated home environments which will be set up within or near active clinical settings (e.g., urgent care facilities). This will be a prospective study conducted at three or more investigational sites located within the United States for the clinical validation of the Metrix Respiratory Panel Test for the detection of SARS-CoV-2, Influenza A, Influenza B, Respiratory syncytial virus, … |
BRAD W KILLINGSWORTH; | 2025-10-16 |
| 52 | Influenza A-associated Pulmonary Aspergillosis in Patients Admitted to The Intensive Care Unit in China: A Retrospective Cohort Study PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Invasive pulmonary aspergillosis (IPA) has traditionally been considered a disease of the severely immunocompromised host. However, emerging evidence over the past decade has identified severe influenza as a significant risk factor for IPA, termed influenza-associated pulmonary aspergillosis (IAPA) . The reported incidence of IAPA in ICU patients ranges from 11% to 32%, with associated mortality exceeding 50% in some cohorts. The pathophysiology of IAPA is thought to involve influenza virus-induced damage to the respiratory epithelium, which impairs mucociliary clearance and disrupts local immune defenses, … |
JIANFENG XIE; | 2026-01-09 |
| 53 | Effect of Aquatic Exercises on Muscle Strength and Quality of Life in Children With Sickle Cell Anemia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Sickle cell anemia is a global public health disorder that affects millions of people across the globe. It is an inherited autosomal recessive hemoglobin condition caused by a beta-globin gene mutation that results in an aberrant sickle cell hemoglobin molecule with glutamic acid replaced by valine at position six of the beta-globin chain. Sickle cell anemia is a hereditary illness characterized by persistent microvascular blockage by sickle-shaped cells, chronic hemolytic anemia, and tissue destruction. Red-cell dehydration, hypoxemia, metabolic acidosis, and hyperthermia are typical vaso-occlusive triggers. Children with sickle cell anemia frequently have poor growth and nutritional status, increased protein turnover, … |
EMAN SAMIR SHALTOUT; | 2026-01-06 |
| 54 | Administration of The Nasal Influenza Vaccine to Children in Daycare or at A Healthcare Facility PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this intervention study is to learn if giving children influenza vaccinations in early childhood education facilities (i.e., daycare) will increase vaccination coverage compared to giving vaccinations only at healthcare. The main question it aims to answer is: • Does offering children nasal influenza vaccine in daycare result in higher proportion of children getting influenza vaccine. Researchers will compare daycare setting and healthcare setting as the location of giving influenza vaccines to children to see if more children will get vaccinated if they have an opportunity to receive nasal influenza vaccine at daycare. Participants in the intervention group will: • Have the opportunity to receive influenza vaccine in the daycare or in the healthcare Participants in the comparison group will: • Have the opportunity to receive influenza vaccine in the healthcare only |
TURKU UNIVERSITY HOSPITAL | 2026-01-22 |
| 55 | Fostering Prosocial Behaviours Against Infectious Diseases Through Awe: A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this randomized control trial is to investigate the impact pf awe on prosocial preventive behaviours against infectious diseases among adults from Hong Kong, Singapore, and ten major cities in Mainland China (Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Chongqing, Chengdu, Wuhan, Xi’an, Nanjing). The main questions it aims to answer are: * Does experiencing awe increase adults’ intentions to engage in prosocial preventive behaviours against infectious diseases, including vaccination, mask wearing, and social distancing? * Does the impact vary across three research sites? |
QIUYAN LIAO; | 2026-02-27 |
| 56 | A Multicenter, Randomised, Double-blind, Placebo-controlled Study to Evaluate The Efficacy, Safety, and Tolerability of The Investigational Product Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to investigate the efficacy, safety, and tolerability of investigational product Ingavirin forte capsules (Valenta Pharm JSC) administered at different doses compared with medicinal product Ingavirin, 90 mg, capsules (Valenta Pharm JSC) in subjects with influenza or other acute respiratory viral infections (ARVIs). |
VALENTA PHARM JSC | 2026-02-19 |
| 57 | The AEVI-Fiji Cohort Study: A Longitudinal Study Assessing The Transmission Risk and Dynamics of Mosquito-borne and Respiratory Viruses in Fiji PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Fiji, an archipelago in the South Pacific comprising 332 islands distributed among 4 health administrative divisions (Central, Western, Eastern, Northern), is particularly vulnerable to the (re-)emergence of arboviruses and respiratory viruses due to its sub-tropical climate, the presence of several mosquito vector species, and connections with many countries in the Pacific, Asia and North America. Over the past decades, the epidemiological landscape of arboviruses has shifted from the sequential circulation of each of the four dengue virus (DENV) serotypes to the emergence of Zika virus (ZIKV) and chikungunya virus (CHIKV), … |
DONALD WILSON; | 2025-12-01 |
| 58 | Addressing The Problem of Recommended But Unfunded Vaccines Through A Co-payment Mechanism in Pharmacies PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this pilot demonstration and evaluation project is to determine the acceptability and feasibility of a co-payment model among the public and providers and assess whether a co-payment model in community pharmacies in Nova Scotia and Ontario increases the accessibility and uptake of recommended but unfunded vaccines. The research questions that guided the development of this study are: * What is the feasibility of implementing a co-payment model for recommended but unfunded vaccines in community pharmacies? * To what extent is a co-payment model for recommended but unfunded vaccines perceived as acceptable to community pharmacists and the public? A co-payment model will be piloted at a maximum of 8 select community pharmacy sites in Nova Scotia (n=4 sites) and Ontario (n=4 sites). Each community pharmacy site will be randomly assigned to pilot one of the steps of the co-payment model for the duration of the demonstration project. At the end of the pilot study, participating pharmacy providers will be asked to complete an online survey about their experiences in implementing the co-payment model into their pharmacy. As part of the co-payment model, recruited members of the public (participants) will choose to receive the vaccine (if eligible) at a reduced cost either for themselves or their dependent (e.g., incapable minor or adult), as part of routine care (following standard pharmacy practice). After receiving the vaccine, the participant will complete an online survey exploring their thoughts on the co-payment model, their satisfaction with the co-payment model, their perception on vaccines in general, and their demographics (such as gender, age, education, race/ethnicity). |
EMILY BLACK; | 2026-03-19 |
| 59 | Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 Vs. 8 Weeks Apart – A Multi-Center Non-Inferiority Placebo-Controlled Observer-Blinded Phase 2 Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Given the recent circulation of avian influenza A(H5N1) clade 2.3.4.4b strains in birds and mammals in North America, Canada procured a supply of Arepanrix™ H5N1 for potential use in persons at high risk of highly pathogenic avian influenza exposure. This vaccine received regulatory approval in 2013, to be given in two doses at least 3 weeks apart. There is limited data on the effect of various intervals between the two doses on immunogenicity and tolerability. In this study two intervals between doses will be compared (3 vs. 8 weeks apart). |
JOANNE LANGLEY; | 2026-01-16 |
| 60 | Implementation and Evaluation of A Pharmacist-led Diabetes Care Pathway in Alberta Community Pharmacies PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: As of 2024, nine percent of Albertans are living with Type 2 diabetes, which increases their risk for cardiovascular disease, stroke, blindness, and kidney failure. Unfortunately, less than half of patients have controlled Type 2 diabetes. We are well aware of the factors which lead to worsening diabetes, … |
ROSS TSUYUKI; | 2026-01-14 |
| 61 | A Multicenter, Randomized, Double-blind, Positive Controlled, Phase III Trial to Evaluate The Safety and Efficacy of ZX-7101A for Oral Suspension in Pediatric Participants Aged 2 to 11 With Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this phase III study is to learn if ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years. The main question it aims to answer is: What medical problems do participants have when taking drug ZX-7101A for oral suspension or Oseltamivir phosphate for oral suspension? Researchers will compare drug ZX-7101A for oral suspension to active comparator: Oseltamivir phosphate for oral suspension to see if drug ZX-7101A for oral suspension works to treat uncomplicated influenza in Pediatric Participants aged 2 to 11 years. |
HANMIN LIU; | 2025-11-19 |
| 62 | A Phase Ⅲ, Randomized, Double-blind, Positive Controlled Clinical Trial to Evaluate The Immunogenicity and Safety of An Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, double-blind, positive controlled phase Ⅲ clinical trial to assess the immunogenicity and safety of Sinovac QIV in pregnant women. A total of 150 healthy pregnant women aged 18\~39 years at 20 to 32 weeks of pregnancy will be enrolled. All participants will be randomized to test group and control group in a ratio of 2:1 and receive one dose of vaccine (0.5 mL) of Sinovac QIV or Vaxigrip QIV, respectively. Blood samples will be collected from participants prior to vaccination and 28 days after vaccination. Moreover, to evaluate trans-placental antibodies, … |
SINOVAC BIOTECH | 2026-01-28 |
| 63 | Mucosal and Systemic Immune Responses Induced By An Intranasal Influenza Live Attenuated Vaccine: A Single-Center, Open-Label, Single-Arm Clinical Study PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a single-center, open-label, single-arm clinical trial designed to evaluate the mucosal and systemic immune responses induced by an intranasal influenza live attenuated vaccine, and to explore the correlation between the two. The study plans to recruit 60 healthy volunteers aged 14-17 years, with a male-to-female ratio of 1:1. Participants and their guardians must be able and willing to comply with the clinical trial protocol and provide informed consent. Eligible participants will receive a single 0.2 mL dose of LAIV prior to the influenza season. Information on participants’ historical vaccination records, baseline demographic data, … |
JING-XIN LI; | 2025-11-18 |
| 64 | PREVENT: Preparedness Through Respiratory Virus Epidemiology and Community Engagement PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their subcontracting institutions. At UCSD and partner sites, the CHARM network will be implemented via the PREVENT project. All PREVENT participants will be consented in to Component A0 (Community Testing) and a subset of A0 participants will be invited to participate and will be consented into the other components: Component A (Ongoing Testing); Component A Sub-study (Immunology); … |
LOUISE LAURENT; | 2025-11-04 |
| 65 | A Phase 2a Randomized, Observer-Blind, Study to Evaluate The Immunogenicity and Safety of MRNA-Based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline’s (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults. |
GLAXOSMITHKLINE | 2026-03-27 |
| 66 | Randomized Controlled Trial of Different Behavioral Text Messages to Improve Influenza Vaccination Rates PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: Influenza infection leads to significant morbidity and mortality each year. Influenza vaccines can reduce the risk of flu and the severity of flu illness, In addition, flu vaccinations can reduce flu complications such as pneumonia or worsening of chronic heart or lung disease. Each year, Kaiser Permanente of Colorado offers influenza vaccines to patients at no cost either at primary care clinic appointments or flu walk-in clinics in the fall prior to the upcoming flu season. In addition, as part of clinic appointment reminder text messages, … |
MICHAEL HO; | 2026-01-28 |
| 67 | A Description of The Proportion, Genotype Distribution of Respiratory Syncytial Virus and The Severity of Disease in Hospitalized Elderly in Vietnam PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This observational, prospective, multicenter study aims to estimate the proportion of RSV infection in adults aged 60 years and older hospitalized due to acute respiratory infections or exacerbation of cardiopulmonary disease. |
TAM ANH RESEARCH INSTITUTE | 2025-11-20 |
| 68 | Multicenter, Double-blind, Placebo-controlled, Randomized, Parallel-group Clinical Trial of The Efficacy and Safety of Rengalin in The Treatment of Cough in Acute Viral Upper Respiratory Tract Infections Tract Infections in Children During The Epidemic Growth of Influenza and ARVI PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the efficacy and safety of liquid dosage form of Rengalin in the treatment of cough in acute viral upper respiratory tract infections infections in children in during the epidemic growth of influenza and ARVI. The main questions it aims to answer are: Investigators will compare the liquid dosage form of Rengalin to a placebo (a look-alike substance that contains no drug) to see if Rengalin in the liquid dosage form works for cough in acute viral upper respiratory tract infections in children. Participants will: Take the liquid dosage form of Rengalin or placebo per os 5 ml per administration 3 times a day for 7 days. |
ASMIK ASATRYAN; | 2026-02-13 |
| 69 | Reducing Respiratory Virus Transmission in Bangladeshi Classrooms PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This study will test if affordable air cleaning devices (box fans with a filter attached and/or ultraviolet light lamps) installed in classrooms can reduce the number of viral respiratory illnesses schoolchildren experience. |
STEPHEN P LUBY; | 2025-04-02 |
| 70 | The Dynamics of The Immune Responses to Repeat Influenza Vaccination Exposures (DRIVE III) Study – A Randomized Controlled Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study will provide novel insight into the effects of repeat influenza vaccination with Flublok and FluMist on the strength and breadth of immune responses to influenza, the mechanisms underlying heterogeneity in vaccine response and vaccine failure, and biological factors that could explain variation in influenza vaccine effectiveness. |
BENJAMIN J COWLING; | 2025-12-09 |
| 71 | CMV-associated Immunomodulation in Renal Transplant Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation. |
ALEXANDRA SERRIS; | 2025-09-12 |
| 72 | A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate The Safety and Efficacy of CD388, A Novel Long-Acting Antiviral Conjugate, for The Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate how well CD388 works in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, when given as a single dose via 3 subcutaneous (SQ) injections to adult and adolescent participants who are at higher risk of developing influenza complications, and to evaluate the safety and tolerability of CD388, as compared to placebo. |
CIDARA THERAPEUTICS | 2026-02-23 |
| 73 | Immunogenicity and Safety of Consecutive High-Dose Vs. Standard-Dose Influenza Vaccines Administered Over Successive Seasons in Lung Transplant Recipients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This will be a follow-up study to the Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Center. Lung transplantation is a life-saving therapy for patients with advanced lung disease, and is also associated with an improvement in quality of life. However, due to the need for life-long immunosuppression to prevent acute cellular rejection and chronic lung allograft dysfunction (chronic rejection), lung transplant recipients are at risk for developing major infections. In fact, one-year survival is 85%, … |
NATASHA HALASA; | 2025-10-07 |
| 74 | Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial To Evaluate The Safety And Immunogenicity Of The Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) From Instituto Butantan, In Adults And The Older Adults PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to demonstrate the safety and immunogenicity of two formulations of the monovalent influenza vaccine candidate A (H5N8) (inactivated, fragmented, and adjuvanted with IB160) from the Instituto Butantan in adults and older adults, to be developed for situations of pandemic, epidemic or outbreak of avian type A/H5 in humans, in the context of pandemic preparedness. |
BUTANTAN INSTITUTE | 2026-04-02 |
| 75 | A Double-Blinded, Randomized Influenza Virus Challenge Trial of Recombinant Influenza RG-A/Arkansas/08/2020 (pH1N1) in Healthy Adults to Assess Safety and Optimal Infectious Dose PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This protocol describes a clinical trial to develop and validate a Controlled Human Infection Model (CHIM) for influenza A/Arkansas/08/2020 (pH1N1). The study is designed to determine the optimal infectious dose of the pH1N1 challenge strain for use in future clinical trials evaluating influenza countermeasures. The study will enroll and challenge adult volunteers with the pH1N1 influenza virus challenge or sham inoculations. Given the adaptive design of this trial, the potential number of participants can vary. Depending on the pathway recommended by the PSRT and followed in the Trial Schema, the study population can range from around 30 to 120. However, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-03-13 |
| 76 | VITAL: Vaccination, Immunity, Time-restricted Eating, Aging and Lifestyle PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this study is to investigate the effects of a four-week time-restricted eating (TRE) intervention on autophagy, immune function, and vaccine response to a seasonal influenza and COVID-19 vaccines in older healthy subjects. |
SEBASTIAN HOFER; | 2025-09-18 |
| 77 | EVax-3: Human Upper and Lower Airway Mucosal Immune Response to FluMist Vaccination PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to measure the immune response in the blood, nose, and lungs after participants receive either the FDA-approved inactivated influenza vaccine or the FDA-approved intranasal FluMist vaccine. The study will evaluate immune responses in groups of healthy, non-pregnant, … |
PHILIP MUDD; | 2025-09-17 |
| 78 | Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate The Efficacy, Immunogenicity and Safety of One Dose of OVX836 Influenza Vaccine 480μg, After Intramuscular Administration in Healthy Subjects Aged 18-59 Years PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The present study will evaluate the efficacy, immunogenicity and safety of one dose of OVX836 influenza vaccine 480μg, after intramuscular administration in healthy subjects aged 18-59 years. |
OSIVAX | 2025-12-17 |
| 79 | Study on Carotenoid-Based Instrumental Index PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Nu Skin (China) Daily-Use\&Health Products Co.,Ltd. has developed biophotonic scanners based on Raman spectroscopy, which measures skin carotenoid levels through hand skin scanning. In this study, the new Prysm device, which adopts new technology in a lower cost and more portable form, was used to measure skin carotenoid levels in a population, and the relationships between these levels and dietary habits and lifestyle factors were analyzed. The collected data included basic demographic information such as age, gender, smoking status, use of health products or nutritional supplements, and exercise habits, … |
CHINANORM | 2025-09-30 |
| 80 | Study of The Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure – CHRONOVAX 2 PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Immune response to influenza vaccine in patients with chronic renal insufficiency. |
GOSSET CLÉMENT; | 2025-09-11 |
| 81 | Effectiveness of Nudge and Motivational Interviewing Interventions to Improve Influenza Vaccination Uptake Among Healthcare Workers in China: A Two-phase Randomized Controlled Trial PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to learn if nudge-based interventions and motivational interviewing work to improve influenza vaccination uptake among healthcare workers in China. A two-phase randomized controlled trial will be conducted in community hospitals across China, targeting healthcare workers as participants. The main questions are: Do nudge-based interventions increase vaccination rates among healthcare workers? Does motivational interviewing increase vaccination compliance among those who remain unvaccinated after the phase 1? In phase 1, community hospitals will be randomized as units into three arms: standard nudge group, personalized nudge group, and a control group. In phase 2, … |
LIXIN HAO; | 2025-09-11 |
| 82 | A Phase 4, Multicenter, Cluster Randomized, Open-label, Intervention Versus Usual Care, Controlled Study on The Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma recurrence at 3 months and other related outcomes (acute asthma relapse, asthma control). |
CARLOS A. CAMARGO; | 2025-09-17 |
| 83 | Observational Study on The Role of Chest Ultrasound in Patients With Respiratory Tract Infections PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Respiratory tract infections are a major cause of hospitalization among pediatric and adult patients, regardless of the cause, whether viral or bacterial. It is critical to stratify each patient’s risk to predict the subsequent clinical course. Point-of-care chest ultrasonography in parallel with clinical evaluation has been found to be an effective tool to assess the severity of pathology. A number of scores have been validated on the basis of the ultrasound picture. Currently, a growing interest is directed toward the unambiguous validation of an ultrasound score that can predict the patient’s outcome in terms of hospitalization, ICU admission, … |
ANTONIO GATTO; | 2025-09-02 |
| 84 | VRC 329: A Phase I Open-Label, Clinical Trial to Evaluate The Safety, Tolerability, and Immunogenicity of A Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (STEMos1) With and Without ALFQ Adjuvant in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Influenza (flu) is a contagious respiratory illness caused by viruses. Flu symptoms can range from mild to severe, and the illness can be fatal. Vaccines help the body learn to prevent or fight infections such as flu. Some vaccines are combined with adjuvants. Adjuvants are special salts or fats that help vaccines work better. Researchers are looking for ways to make flu vaccines more effective. Objective: To test a new flu vaccine with and without a new adjuvant. Eligibility: Healthy adults aged 18 to 50. They must have had at least 1 flu vaccine since 2020. Design: Participants will have 12 clinic visits over 15 months. The vaccine is given as an injection into the muscle of the upper arm. Participants will be vaccinated during 2 visits spaced 4 months apart. Half will receive just the vaccine; half will receive the vaccine plus the adjuvant. They will be monitored for at least 30 minutes after each shot. Participants will keep a diary for 7 days after each shot. They check their temperature every day and record any symptoms. Participants will have 10 follow-up clinic visits plus 4 phone calls. They will have 4 to 10 tablespoons of blood drawn at each clinic visit. Fluid samples will be collected from their nose and mouth. They will be checked for any health changes. Participants may opt to undergo apheresis: Blood will be taken from the body through a needle inserted into a vein. The blood will pass through a machine that separates out the white blood cells. The remaining blood will be returned to the body through a different needle. |
LESIA K DROPULIC; | 2026-01-22 |
| 85 | Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is being done to understand and measure how the immune system responds to and remembers different types of vaccines. To do this, four vaccines approved by the U.S. Food and Drug Administration (FDA) will be given simultaneously to participants. Participants will be volumteers who are healthy adults (18 years old or older) and willing to receive the yearly trivalent inactivated influenza vaccine (TIV), the tetanus, diphtheria, and acellular pertussis vaccine (Tdap), the nonvalent HPV (HPV) vaccine, hepatitis A virus (HAV) vaccine and undergo study procedures. Procedures will include: * medical history relevant to the study, … |
PATRICK D OLSON; | 2026-03-25 |
| 86 | A Phase 2a Randomized, Observer-Blind, Study to Evaluate The Immunogenicity and Safety of MRNA-Based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age And Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKlines (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults. |
GLAXOSMITHKLINE | 2025-11-14 |
| 87 | Increasing Men’s Engagement in Preventive Healthcare Through An Enhanced Cocoon Vaccination Strategy PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to understand if offering a high touch engagement with healthcare center catered to men and bedside vaccine access in a birthing center increases men’s engagement in preventive healthcare. The main questions it aims to answer are: Does access to vaccinations and overall health education for men lead to increased uptake of vaccines? Does access to vaccinations and overall health education for men lead to increased engagement in overall healthcare of male identifying support persons. Researchers will compare three arms (one that receives an offer of vaccines at bedside in the birthing clinic, … |
RANDY VINCE; | 2025-12-12 |
| 88 | Enhancing Vaccination Uptake Through Points Redemption Based Financial Incentives and Digital Platforms: An Open-label Cluster Randomized Controlled Trial Utilizing Community Mobilization and Empowerment Strategies PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The overall goal is to develop and optimize a health digital platform and points redemption-based financial incentive interventions for the promotion of non-National Immunization Program (non-NIP) vaccination uptake and related preventative behaviors in China, and formulate a low-cost, labor-saving and replicable pattern. The primary objective is to develop and optimize a digital platform-based point-redemption and financial incentive system and evaluate the effectiveness of the interventions for improving non-NIP vaccines coverage and related preventive behaviors.The main questions it aims to answer are: H1: Participants allocated to the intervention group will demonstrate a 3% increase in vaccine doses of targeted non-NIP vaccines, … |
BO YAN; | 2025-07-10 |
| 89 | A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate The Protective Efficacy and Safety of A Nasal Spray Live Attenuated Influenza Vaccine in Adults Aged 18-59 Years PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: A Clinical Trial to Evaluate the Protective Efficacy and Safety of a Nasal Spray Live Attenuated Influenza Vaccine (LAIV) in Adults Aged 18-59 Years Post-Vaccination |
CHANGCHUN BCHT BIOTECHNOLOGY | 2025-08-21 |
| 90 | A Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate The Safety, Efficacy, and Pharmacokinetics of Suraxavir Marboxil for Suspension in Pediatric Patients (2 to <12 Years) With Uncomplicated Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the safety, efficacy and pharmacokinetics of Suraxavir Marboxil compared with oseltamivir in Pediatric Patients (2 to \<12 Years) with Uncomplicated Influenza. |
JIANGXI KERUI PHARMACEUTICAL | 2025-08-08 |
| 91 | Unravelling The Measles Paradox: A Disease Associated With Both Immune Suppression and Immune Activation PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The measles (MeV) paradox refers to an apparent contradiction: natural measles causes a transient but profound immune suppression putting patients at risk for opportunistic infections for years, while at the same time MeV infection induces robust immune activation leading to lifelong protection against measles. In this protocol, we test our hypothesis that natural measles causes immune amnesia by altering the composition of circulating immune memory cells. In comparison to the prior studies performed during the 2013 outbreak, we will specifically determine \[1\] to what extent pre-existing immunity is reduced, \[2\] for how long this functional immune suppression can be detected, … |
CORINE GEURTS VAN KESSEL; | 2025-12-05 |
| 92 | Clinical Feasibility of The BinaxNOW™ COVID-19/Flu A&B Combo in The Southern Hemisphere PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The study is designed as a clinical feasibility, to investigate the positive and negative percent agreement (PPA and NPA) of the BinaxNOW™ COVID-19/Flu A\&B Combo against a highly sensitive PCR method(s) in symptomatic patients suspected of SARS-CoV-2 or influenza infection when nasal swabs are self-collected by the patient/lay user. |
ABBOTT RAPID DX | 2025-04-15 |
| 93 | A Phase 1 Study to Evaluate The Safety and Immunogenicity of Two Doses of A Novel H5 Antigenically Central (AC)-Anhui MRNA-LNP Vaccine in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a phase 1, multicenter, randomized, double-blind trial of two influenza A/H5 mRNA-based vaccines on healthy adult participants, 18-49 years of age. Stage 1 will serve as the open-label, dose finding stage. The first 10 participants will receive 12.5 mcg of H5 AC-Anhui RNA vaccine (Group 1), and the second 10 participants will receive 25 mcg of H5 AC-Anhui RNA vaccine (Group 2). After Protocol Safety Review Team (PSRT) review of reactogenicity and safety data through Day 8 for both Groups 1 and 2, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2026-01-30 |
| 94 | Research on The Cognition and Practices of Chinese Cardiologists Regarding Influenza Vaccination for Patients With Chronic Coronary Syndrome PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This long-term single-center cross-sectional study evaluates physicians’ knowledge of influenza vaccination in CCS patients through collected feedback, while identifying knowledge gaps and misconceptions regarding vaccination. By analyzing factors influencing physicians’ recommendation practices, it provides evidence to guide future educational and policy interventions. Ultimately, the study aims to enhance cardiologists’ vaccination awareness, thereby optimizing CCS patient management and reducing influenza-associated complications and mortality. |
THE AFFILIATED HOSPITAL OF HANGZHOU NORMAL UNIVERSITY | 2025-06-04 |
| 95 | Effectiveness of The Influenza and Tdap (tetanus, Diphtheria, Acellular Pertussis) Vaccination Educational and Learning Module (InTroDuce-Programme) in Improving Knowledge and Future Uptake of Vaccination Among Pregnant Mothers in Primary Care Clinics: A Randomised Control Trial Secondary IDs PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this InTroDuce-Programme interventional trial aims to test whether a web-based educational program can improve pregnant women’s knowledge about Influenza and Tdap vaccinations and increase their intention to get vaccinated in the future. The main questions it aims to answer are: Does the InTroDuce-Programme increase knowledge and future intention of pregnant mothers to get vaccinated against Influenza and Tdap? How does demographic factors, … |
LAU HUNG CHIUN; | 2025-02-07 |
| 96 | Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose Vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: This prespecified analysis will pool the datasets from two pragmatic randomized trials evaluating the relative vaccine effectiveness of high-dose vs. standard-dose influenza vaccine against severe clinical outcomes: the DANFLU-2 (A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults) trial and the GALFLU (Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia, … |
TOR BIERING-SØRENSEN; | 2025-09-12 |
| 97 | A Pilot Study of The Effects of Pre-Existing Immunity on Influenza A/Texas/71/2017 (H3N2) Virus Shedding After Human Challenge in Healthy Participants PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a research study to understand what happens when a person is infected with influenza (flu) and how the body controls the infection. Healthy participants (challenge) will be infected with a strain of flu (H3N2), … |
DANIEL HOFT; | 2025-07-14 |
| 98 | A Randomized Controlled Pilot Trial Comparing 2 Non-invasive Airway Clearance Methods for The Prevention of Early-onset Ventilator-associated Pneumonia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Severe trauma, head trauma, stroke and resuscitated cardiac arrest patients requiring endotracheal intubation and mechanical ventilation are at high risk of early-onset ventilator-associated pneumonia (EO-VAP). A short course of systemic antibiotic is recommended for prophylaxis. This study intends to assess the safety and efficacy of 2 alternative mechanical non-invasive airway clearance techniques in the prevention of EO-VAP in an open label randomized pilot trial of 20 subjects per study group i.e., 60 cases. The interventions will be in place for 7 days and the observational periods will be 14 days. |
MIGUEL SANCHEZ GARCIA; | 2025-03-07 |
| 99 | In-depth Immunological Analysis of Airway Immunity Following Nasal Live Attenuated and Intramuscular Influenza Vaccine PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The study aims to compare the effectiveness of live attenuated influenza vaccines (LAIV) and intramuscular-inactivated vaccines (IIV) in healthy individuals aged 18-49. It will investigate cellular and humoral responses, identify immunological markers for targeted vaccine improvement, and establish a collaborative platform for accelerated immunological and clinical vaccine research. |
JENS-ULRIK STÆHR JENSEN; | 2026-03-25 |
| 100 | Development of A High-throughput Serological Testing Platform for Mass Screening Purposes of Both Pediatric and Adult Cohorts- Adult Cohort PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In the case of large emergency serosurveys, innovation in the sampling techniques is an often neglected, but relevant aspect to facilitate the enrolment of subjects in both adult and paediatric populations. Further, … |
FRANCESCO BONFANTE; | 2025-04-23 |
| 101 | BCG2-DTP3: Providing BCG Revaccination With The Third Dose of Diphtheria-tetanus-pertussis Vaccine to Improve Female Survival in Africa PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Studies in low-income countries show that vaccines can have important non-specific effects on other infections. Live BCG vaccine can train the immune system and reduce susceptibility to unrelated infections. In contrast, non-live diphtheria-tetanus-pertussis-containing (DTP) vaccine enhances susceptibility in females: DTP vs no DTP is associated with 2-fold higher mortality, and in DTP-vaccinated children, … |
CHRISTINE STABELL BENN; | 2025-06-12 |
| 102 | Investigation of Impact of Milk Consumption on H5 Influenza Detection in Respiratory Specimens PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to determine whether drinking pasteurized milk (milk heated to kill harmful germs) that contains inactive particles of a flu virus called A(H5) could lead to the detection of the virus in the nose or throat. Inactive particles are not capable of causing disease. The results will help the Centers for Disease Control and Prevention (CDC) better understand how milk consumption could affect flu surveillance. Investigators also want to see if the body produces antibodies in response to this milk consumption. |
DANIEL S. GRACIAA; | 2025-10-14 |
| 103 | A Randomized, Blinded Phase I./II Clinical Trial to Evaluate The Safety, Tolerability, and Immunogenicity of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This clinical trial adopts a seamless design of phase I/II, conducted in two stages: phase I and phase II. Phase I is the age/dose ramp up stage, and phase II is the dose expansion stage.The purpose of this clinical trial is to evaluate the safety and tolerability of different doses of Influenza Vaccine (Split Virion), Inactivated, Quadrivalent, ZFA02 Adjuvant，explore the immunogenicity of the vaccine, and determine the appropriate dose for later clinical trials of this product. |
FEI JIN; | 2025-11-20 |
| 104 | A Controlled Human Infection Study of A Recombinant H3N2 (A/Texas/71/2017, Clade 3C3a) Influenza Virus in Healthy Adults in Australia PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study will examine how the immune system responds to a flu virus (H3N2) during and after infection in health adults aged between 18 and 50 while in an inpatient facility. The study uses a specific flu virus called the H3N2 influenza challenge virus, that was produced specifically for use in clinical research in controlled conditions. From a previous study, mild to moderate symptoms are expected. This is the first time that a flu challenge study has been undertaken in Australia. |
GAIL CROSS; | 2025-06-12 |
| 105 | Escape 10 Study. Epidemiology and Determinants of Outcomes of Severe Community-acquired Pneumonia in The Elderly PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The ESCAPE 10 study is a multinational, retrospective, observational cohort study that aims to investigate the epidemiology and outcome determinants of severe community-acquired pneumonia (sCAP) in elderly patients (≥65 years). Conducted across multiple European countries, the study will include at least 500 patients admitted to acute care hospitals with radiologically confirmed sCAP, with enrollment distributed evenly between epidemic (winter) and non-epidemic (summer) seasons. The primary objective is to assess 28-day mortality. Secondary objectives include evaluating in-hospital mortality, pneumonia-related complications, Intensive Care Unit (ICU) stay, ventilation needs, and identifying clinical risk factors associated with poor outcomes. Additionally, … |
JOAN SABATER RIERA; | 2025-07-17 |
| 106 | Comorbidity Management in Rheumatic Disease: Assessing A Potential Care Gap in Patients With Rheumatoid Arthritis PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Rheumatoid arthritis is a disease where the immune system attacks the body by mistake, causing inflammation of the joints and other body parts. People with rheumatoid arthritis are at higher risk of infections, heart problems, and bone issues compared to others. They regularly see rheumatologists, arthritis care physicians, to manage their disease. However, … |
CASSANDRA SCHULZ; | 2025-10-07 |
| 107 | Routine Application of Point-of-care PCR Test to Identify and Direct Therapy for Acute Respiratory Infection in The Emergency Department (RAPID-ARIED) Trial PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The RAPID-ARIED Trial is a pragmatic, single-centre, parallel group, open-label, randomised controlled trial to be conducted in the Accident and Emergency Department of Queen Mary Hospital in Hong Kong. The investigators aim to 1) to evaluate the clinical impact of the routine application of point-of-care polymerase chain reaction (PCR) testing for targeted respiratory pathogens in the emergency department (ED) for adult patients with acute respiratory infections (ARIs) on the hospital length of stay (LOS), antiviral and antibiotic use during influenza seasons or future waves of COVID-19; … |
LAM PUI KIN; | 2025-03-28 |
| 108 | Evaluation of The Diagnostic Performance of The DM-DIV (in Vitro Diagnostic Medical Device) TestNPass for The Diagnosis of SARS-CoV-2 Infection Using A Nasopharyngeal Sample PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The COVID-19 pandemic has created a major global health crisis that requires a rapid and effective response, particularly in the field of diagnostics. The first tests used, based on PCR (polymerase chain reaction) performed through a deep nasopharyngeal swab, have shown their limitations in controlling the epidemic. The current need is to develop new tests that are rapid, affordable and easy to use, and that can be used on a large scale in outpatient settings to reduce the burden on healthcare teams. In addition, … |
UNIVERSITY HOSPITAL GRENOBLE | 2025-04-08 |
| 109 | VRC 328: A Phase I Open-Label Clinical Trial to Evaluate The Dose, Safety, Tolerability, and Immunogenicity of Mosaic Hexavalent Influenza Vaccine VRC-FLUMOS0116-00-VP (FluMos-v2) With and Without ALFQ Adjuvant in Healthy Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Background: Vaccines help the body learn to fight infections. Some vaccines are combined with adjuvants, which are added substances that make vaccines work better. FluMos-v2 is an experimental flu vaccine; ALFQ is an experimental adjuvant. Objective: To test FluMos-v2, with and without the ALFQ adjuvant, … |
LASONJI A HOLMAN; | 2026-02-23 |
| 110 | Role of The Nuclear Pore Component RANBP2 in Inflammatory Responses to Viral Infections PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this controlled, pathophysiological, exploratory interventional study is to compare the inflammatory phenotype of circulating immune cells, basal and following stimulation, from Acute Necrotizing Encephalopathy Type 1 (ANE1) patients with those from sex- and age-matched donors who do not carry the mutation.To date, no study has investigated the molecular mechanisms regulating the inflammatory response in ANE1 disease directly on patient samples. The primary endpoint in individuals in the mutated RANBP2 arm is an inflammatory phenotype (hyperinflammatory monocytes, secretion of pro-inflammatory cytokines, anti-glycoprotein autoantibodies), … |
PIERRE MEYER; | 2026-02-05 |
| 111 | A Phase 1/2, Parallel-group, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Ranging Study to Evaluate The Safety and Immunogenicity of A Second Generation Structurally Designed Pandemic Influenza H5 HA MRNA Vaccine in Healthy Adults Aged 18 Years and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this phase 1/2 study is to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against pandemic H5 influenza virus (pandemic flu H5 hemagglutinin (HA) mRNA SD2) in healthy younger and older adults. The study will aim to identify the appropriate dose for further clinical development of a potential pandemic response vaccine. The study also includes an extension phase for one of the 3 dose levels of the pandemic flu H5 HA mRNA SD2 vaccine to collect additional safety and the immunogenicity data for this specific dose of the vaccine. During this Extension Phase, an additional 480 participants will be randomized according to a 1:1 ratio and stratified by age (≥ 18 to \< 65 years and ≥ 65 years) to receive either the low dose of the pandemic flu H5 HA mRNA DS2 vaccine (Group 1) or placebo (Group 4). This extension will enhance the safety database and improve precision of the immunogenicity results for the selected dose while preserving the original study design integrity. The study duration per participant will be approximately 13 months. There will be two injections of placebo or pandemic flu H5 mRNA vaccine 21 days apart at high, medium and low doses. Study visits/contact include: 7 study visits and 1 telephone call. Vaccination visits (including blood samples) will occur at Day 01 and Day 22. Short-term follow-up visits (including blood samples) will occur 8 and 21 days after each injection. Participants will be also followed up (including blood samples) at 3 and 6 months after 2nd injection, and at 12 months after 2nd injection for safety. |
SANOFI | 2026-01-16 |
| 112 | A Two-arm, Non-randomised, Open-label Experimental Medicine Study to Compare Immune Responses Between Healthy Volunteers Aged 18-40years Receiving Either An Intranasal Live-attenuated Influenza Vaccine or Viral Challenge With GMP Influenza A/Belgium/4217/2015 (H3N2) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This experimental medicine study aims to compare immune responses in healthy adult volunteers aged 18-40 years against influenza vaccination and infection in the upper and lower respiratory tract, following administration of a live-attenuated influenza vaccine delivered by nasal spray versus influenza A (H3N2) viral challenge. |
CHRISTOPHER CHIU; | 2025-05-02 |
| 113 | Respiratory Virus Infections in Hospitalized Patients With Acute Heart Failure Syndrome: A Prospective Multi-center Observational Study PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Patients admitted to the cardiology department with acute heart failure who have a nasopharyngeal respiratory virus PCR test performed within 72 hours of admission will be enrolled in the study cohort. The detection rate of respiratory viruses including influenza virus, RSV, and coronavirus will be analysed. The investigators will also look for seasonal changes in the frequency of respiratory viruses and differences in the clinical presentation of heart failure based on respiratory virus infection. |
MINJAE YOON; | 2026-03-11 |
| 114 | Community-based Behavioral Intervention to Increase COVID-19 and Influenza Vaccination for African American/ Black and Latino Persons: An Optimization Randomized Controlled Trial Related Papers Related Patents Related Grants Related Experts Highlight: The proposed study responds to the need for community-engaged interventions to increase vaccine uptake among populations experiencing health disparities. We focus on COVID-19 and influenza vaccination, both of which now require annual vaccines. Among those at highest risk for morbidity, hospitalization, and mortality are African American/Black and Latino (ABBL) persons who are not up-to-date on these vaccinations. Only 20-28% of adult AABL persons are up-to-date on COVID-19 vaccination, compared to 31% of White persons, … |
NEW YORK UNIVERSITY | 2025-04-29 |
| 115 | A Phase 1, Parallel, Randomized, Multi-center Study to Evaluate The Safety and Immunogenicity of Different Formulations of Multivalent Influenza and Respiratory Syncytial Virus (RSV)/Human Metapneumovirus (hMPV)/Parainfluenza Virus Type 3 (PIV3) Vaccines in Healthy Participants 18 to 49 Years of Age PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus / parainfluenza virus type 3 vaccine in healthy participants 18 to 49 years of age. A lipid nanoparticle will be used in this study. Overall, … |
SANOFI | 2026-01-16 |
| 116 | Conversations With AI Chatbots Increase Short-Term Vaccine Intentions But Do Not Outperform Standard Public Health Messaging PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to test whether short conversations with large language model (LLM) chatbots can persuade vaccine-hesitant parents to vaccinate their children against human papillomavirus (HPV). The study compares two chatbot styles to official public health information and to a no-message control. Parents of HPV-eligible children first complete a survey about their attitudes toward the HPV vaccine and their main concerns. They are then randomly assigned to read public health materials, have a three-minute conversation with either a default-style chatbot or a conversational-style chatbot tailored to their concern, … |
UNIVERSITY OF PENNSYLVANIA | 2025-08-20 |
| 117 | Surveillance of Nosocomial Influenza at Edouard Herriot University Hospital, Lyon, France Related Papers Related Patents Related Grants Related Experts Highlight: Hospital-Acquired Influenza (HAI) is closely linked to the intensity of influenza in the community. HAI is associated with significant morbidity, mortality and extra costs due to prolonged hospital stay. The incidence of laboratory confirmed HAI has been reported rarely. The proportion of HAI among influenza cases was 11.38% (95% Confidence Interval: 5.19%-19.55%) in a meta-analysis of 14 studies. In France, a prospective surveillance study of adults with Influenza-Like Illness (ILI) over 11 years, … |
HOSPICES CIVILS DE LYON | 2025-03-11 |
| 118 | A Phase 2, Randomized, Observer-blind, Active-control Study to Evaluate The Immunogenicity, Reactogenicity, and Safety of MRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age. |
MODERNATX | 2025-10-20 |
| 119 | Dissecting Human Immune Responses To Infection With Influenza or SARS-CoV-2 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the virus-specific immune response in people who are symptomatic with confirmed influenza or COVID-19. We will study the immune response of people who have and who have not been vaccinated with the seasonal influenza and COVID-19 vaccines within the past year. All participants will have data collected and blood, saliva, and nasal swabs performed at five separate visits; 1) at study enrollment, 2) on study day 7, 3) on or between study days 10 to 28, 4) on study day 90, … |
PHILIP MUDD; | 2026-03-12 |
| 120 | The Effects of Woodsmoke Exposure on Nasal Immune Responses to Influenza Infection in Normal Human Volunteers PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production. |
MEGHAN REBULI; | 2025-02-24 |
| 121 | Evaluating The Clinical Utility of Modified Ventilator-Associated Event Criteria in Predicting ICU Mortality and Ventilator Duration: Can Less Restrictive Definitions Improve Prediction? PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Study design: A prospective observational study * Study setting: The study will be carried out in the department of critical care medicine, Benha university hospitals. * Study time: The study time is set to a period of one year from March 2025 to March 2026. |
AMAL HOSAM ELDIN MOHAMED FAHMI; | 2025-10-08 |
| 122 | A PHASE 1/2 RANDOMIZED, DOUBLE-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to learn about how the flu and COVID vaccines act when given alone or when mixed together. This study is seeking healthy participants aged 18 or older. All participants in this study will receive only 1 shot to their arm, either a flu or COVID vaccine, alone or mixed. Participants will take part in this study for about 6 months, and participants will need to visit the clinical study site at least 4 times. |
BIONTECH SE | 2026-01-26 |
| 123 | A Randomized, Blinded, Positive-controlled Phase III Clinical Trial of Quadrivalent Influenza Vaccine (split Virion) in People Aged 3 Years and Above PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, blinded, active-controlled phase III clinical trial to evaluate the immunogenicity and safety of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above). Primary immunogenicity endpoints are the geometric mean titers, geometric mean fold increases, seropositive rates, and seroconversion rates of anti-influenza virus HI antibodies for all types 30 days after immunization, and primary safety endpoints are the occurrence of safety events after vaccination including the incidence of adverse events/adverse reactions within 30 minutes/7 days/30 days after immunization, … |
TENG HUANG; | 2025-10-15 |
| 124 | Influenza Human Challenge Model Using H3N2 (A/Texas/71/2017 (H3N2), Clade 3C3a) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is designed to help us better understand how the immune system responds to the flu and how flu is transmitted in the environment. The ultimate goal is to develop better vaccines and drugs to protect against or fight the flu. This study will describe how the body’s immune system responds to the flu virus during and after infection and how the flu virus is transmitted in the environment. The study will use a flu virus called A/Texas/71/2017 (H3N2), … |
NADINE ROUPHAEL; | 2026-03-03 |
| 125 | Pilot Study Enhancing Telemedicine Care Delivery for Adults With Complex Type 2 Diabetes PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this pilot clinical trial is to assess feasibility of an intervention to deliver comprehensive, high-quality diabetes care through telemedicine among adults with type 2 diabetes who use insulin and have multiple chronic health conditions. The main question it aims to answer is: Is an enhanced telemedicine intervention for type 2 diabetes compared to usual telemedicine care feasible? Researchers will compare the enhanced telemedicine intervention to usual telemedicine care to see if there are differences in patient satisfaction or preliminary clinical outcomes. Participants will complete 2-3 telemedicine diabetes care visits over approximately 6 months, … |
MARGARET ZUPA; | 2025-04-15 |
| 126 | Effect of Oral Supplement Intervention on Influenza Vaccine Efficacy: A Randomized Controlled Clinical Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this clinical trial is to explore the efficacy of fatty acid and bile acid based supplements on enhancing influenza vaccine immune response in adults aged 60-70 years. The objectives of this study are: 1. To explore the efficacy of fatty acid and bile acid based supplements on enhancing flu vaccine immune response. 2. To evaluate the safety of fatty acid and bile acid use in elders. 3. To explore the potential role of microbiota in regulating immune response. This study will conduct a randomized clinical trial to compare the efficacy of fatty acid / bile acid (Tauro Ursodesoxy Cholic Acid, TUDCA)supplements on enhancing vaccine immune response. The antibody’s titer and safety indicators after influenza vaccination will be evaluated. Study process are: 1. Participants will be required to intake the assigned supplement or placebo daily for 25 days; 2. Receive a influenza vaccine on day 4; 3. Provide blood samples three times and stool samples twice at base line and endpoint respectively; 4. The antibody’s titer and safety indicators will be analyzed and compared among groups. This study aims to establish a theoretical foundation for utilizing nutritional strategies to enhance vaccine-induced immune responses and to provide a scientific framework for developing oral vaccine boosters. |
AI ZHAO; | 2025-02-14 |
| 127 | A Phase 3, Randomized, Observer-Blinded, Study to Compare The Safety and Immunogenicity of 3 Lots of SARS-CoV-2 RS Nanoparticle and Trivalent Hemagglutinin Nanoparticle Influenza Combination Vaccine With Matrix M™ Adjuvant in Participants ≥ 65 Years of Age Related Papers Related Patents Related Grants Related Experts Highlight: The goal of Phase 3 Study is Comparing the Safety and Immune Response of Three Batches of a COVID-19 and Flu Combination Vaccine in Seniors Aged 65+ |
NOVAVAX | 2025-03-11 |
| 128 | Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup. |
ASTRAZENECA | 2026-03-10 |
| 129 | Evaluating Immune Imprinting in The Context of Influenza Virus Infections PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Cellular and humoral immune responses in individuals with active influenza infection will be assessed. Each year, up to 50 participants will be enrolled. The investigators hypothesize that influenza infection will elicit mostly memory immune responses rather than de novo immune responses to infection. |
UNIVERSITY OF PENNSYLVANIA | 2026-02-05 |
| 130 | Analysis of Single Respiratory Viral Infections Versus Co-infections in The Post-pandemic Era: Prevalence and ICU Needs in Hospitalized Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The objective of our study is to investigate the prevalence of viral respiratory infections in inpatients following the end of the pandemic. Additionally, the prevalence of patients co-infected with multiple viruses simultaneously will be assessed. In the secondary part of the study, the development of respiratory tract infections, the need for intensive care, and mortality rates within seven days will also be evaluated, and risk factors for patients with a more severe clinical course will be statistically calculated. |
ÖZLEM GÜLER; | 2025-07-08 |
| 131 | A Phase I/II, Randomized, Modified Double-blind Study to Investigate The Safety and Immunogenicity of Different Doses of Hexavalent Influenza MRNA HA + MRNA NA Vaccine in Adult Participants 50 Years of Age and Older PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older. |
SANOFI PASTEUR A SANOFI COMPANY | 2025-05-30 |
| 132 | A Randomized, Open-Label Clinical Study on The Efficacy of Baloxavir Marboxil and Oseltamivir for Post-Exposure Prevention of Influenza in A Hospital Setting PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to randomly assign close contacts of hospitalized influenza virus patients to receive baloxavir marboxil prophylaxis, oseltamivir prophylaxis or no antiviral prophylaxis and monitor the incidence of clinical influenza, evaluating the prophylaxis efficiency of antivirals in a hospital setting. |
BIN CAO; | 2025-05-05 |
| 133 | Vaccination Against Influenza Pre-discharge in Patients Hospitalized Due to Heart Failure PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: In patients with heart failure (HF), influenza vaccination should be considered to prevent HF hospitalizations. However, vaccination rates among patients with HF are low, in part because of subjective but common concerns about whether patients with such severe disease should be vaccinated. In this randomized, open-label study, we will investigate whether influenza vaccination before discharge in patients stabilized after cardiac decompensation is safe and improves outcomes over a 6-month follow-up period. |
MICHAŁ TKACZYSZYN; | 2025-07-23 |
| 134 | Prospective Clinical Evaluation of COVID/Flu Detect™ Rapid Self-Test in Symptomatic Subjects for Non-Prescription Over-the-Counter (OTC) Use PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this study is to evaluate the performance of the COVID/Flu Detect™ Rapid Self-Test when used in a home-like setting by lay users. The COVID/Flu Detect™ Rapid Self-Test is an investigational device intended for the qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B protein antigens in nasal swab samples. Participants who are aged two (2) years and older and have symptoms of respiratory illness consistent with SARS-CoV-2 and influenza infection may be enrolled. Participants will use the COVID/Flu Detect™ Rapid Self-Test to self-collect, self-test, … |
INBIOS INTERNATIONAL | 2025-05-22 |
| 135 | Comparison Between Nasopharynx and Orobuccal/Nasal Swabs or Saliva for Detection of Respiratory Viruses (ORASAMP) PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this observational study is to validate the use of less invasive samples (saliva, orobuccal or nasal swabs) than nasopharyngeal swab for testing common and clinically relevant respiratory viruses in children and adults presenting to an emergency departements with symptoms compatible with respiratory tract infection. The main question it aims to answer is: – Is the precision of reverse transcription polymerase chain reaction (RT-PCR) for Influenzavirus A or B, respiratory syncytial virus (RSV), and Rhinovirus, on saliva, … |
PHILIPP JENT; | 2025-06-01 |
| 136 | A Clinical Trial Evaluating The Safety of An Aerosol BCG Controlled Human Infection Model in Assessing The Immunogenicity of Historical BCG Vaccination and Vaccination With ID93/GLA-SE in Healthy Adult Volunteers PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to: 1. Demonstrate the safety of a novel TB vaccine (ID93/GLA-SE) when given to both BCG-vaccinated and BCG-naïve volunteers. 2. Provide preliminary immunogenicity data of this novel TB vaccine (ID93/GLA-SE). This clinical trial will apply an aerosol BCG challenge model involving 48 participants – 24 historically BCG-vaccinated volunteers and 24 BCG-naïve volunteers. Bronchoscopies will be performed 14 days post-challenge to measure BCG recovered from bronchial samples. Blood tests will be taken to look at potential immunological markers of immunity. |
HELEN MCSHANE; | 2025-12-12 |
| 137 | Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate The Efficacy and Safety of Lacticaseibacillus Rhamnosus CRL1505 in The Prevention of Upper Respiratory Tract Infections in A Healthy Paediatric Population PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Randomized, double-blind, placebo-controlled, parallel-group, clinical trial to assess the efficacy of the intake of a probiotic product composed of Lacticaseibacillus rhamnosus CRL1505 strain in reducing or preventing upper respiratory tract infections (URTIs) in a healthy paediatric population. |
BIOITHAS SL | 2025-09-12 |
| 138 | Role of BARriers in IgG-Pathogen Interactions at The Mucosal Surface in Human Airways PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Context. Non cystic fibrosis bronchiectasis (NCFB) is a group of suppurative chronic airway diseases of multiple causes. Bronchiectasis is characterized by an abnormal, irreversible dilatation of the bronchi, airway obstruction, chronic cough, and sputum production. Inhaled polyclonal immunoglobulin G (IgG) is a new therapeutic approach for NCFB. Inhaled IgG is expected to have beneficial effects due to its ability to reduce the range of respiratory pathogens capable of infecting the respiratory tract, decrease the pulmonary load of existing bacterial populations, improve mucociliary clearance by restoring epithelial cell functions, … |
LAURENT PLANTIER; | 2025-12-10 |
| 139 | A Prospective Epidemiological Cohort Study Evaluating Occurrences of Influenza-like Illness in An Urban Population of Healthy Subjects Aged 20-64 Years, Not Vaccinated Against Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This prospective epidemiological cohort study is being conducted in order to generate epidemiological data in support of Osivax’s clinical development of a broad-spectrum influenza vaccine based upon the internal influenza nucleoprotein (NP), i.e., OVX836. |
OSIVAX | 2025-06-25 |
| 140 | A Phase 1, First-in-human, Randomized, Observer-blind, Parallel Design, Controlled, Dose Level and Schedule-finding Study to Evaluate The Safety, Reactogenicity, and Immunogenicity of A Self-Amplifying MRNA Pandemic Influenza Vaccine (ARCT-2304) When Administered to Healthy Adults PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the safety and immune responses of three different dose levels a self-amplifying RNA pandemic influenza vaccine (ARCT-2304) in adults. The key objectives of the study are: * To evaluate safety and reactogenicity of different dose levels of the ARCT-2304 vaccine * To describe the Immune responses of different dose levels of the ARCT-2304 vaccine as measured by hemagglutination inhibition (HAI) and neuraminidase enzyme-linked lectin (ELLA) antibody responses Researchers will compare the results with licensed influenza vaccines to select the most optimal dose level and schedule for vaccine administration in terms of safety and immunogenicity for further development of the vaccine. Participants will receive 2 doses of the ARCT-2304 vaccine or 1 dose of licensed influenza vaccine and 1 dose of placebo. They will be asked: * to complete a daily diary for 7 days after each vaccination, answering questions how they have been feeling on that day. * to provide blood samples at each visit in the clinic * to comply with all study visits and procedures (e.g., be available for planned telephone contacts and unscheduled clinic visits, if required) |
ARCTURUS THERAPEUTICS | 2026-04-03 |
| 141 | A Randomized, Observer-Blinded, Active-Controlled Study to Evaluate The Safety and Immunogenicity of A COVID-19 Influenza Combination Nanoparticle Vaccine and A Standalone Trivalent Nanoparticle Influenza Hemagglutinin Vaccine in Participants ≥ 65 Years of Age PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: This is a medical study where participants will be randomly assigned to receive either a new combination vaccine that protects against both COVID-19 and the flu, or a standard flu vaccine. The researchers conducting the study won’t know which vaccine each participant receives, ensuring their observations are unbiased. This study compares the new combination vaccine to an already available flu vaccine to see how well it works. It’s a large-scale, final-stage study designed to thoroughly check how well the vaccines trigger an immune response (immunogenicity) and how safe they are. |
NOVAVAX | 2025-07-18 |
| 142 | ReMARk: A Multi-level Intervention Addressing Disparities in Rural HPV-related Cancer Prevention: Part 3- Evaluation PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: There are three main objectives of the protocol. First, we will evaluate the added clinical- and cost- effectiveness of parent-targeted motivational aids (reminder/recall and phone-based MI) alone and when combined with community-targeted healthcare access assistance beyond the effects of clinician-targeted training. Second, we will estimate the differential effectiveness of the implementation strategies by patient-level factors (age, race/ethnicity, sex, distance from home to clinic, social vulnerability). Third, we will measure moderation of implementation strategy effectiveness by clinic-level factors (HPV vaccination priority, resources, clinic visit types, scheduling practices, and implementation success). Within 11 rural North Central Florida counties, … |
STEPHANIE STARAS; | 2025-09-09 |
| 143 | Evaluation of The Effect of Consensus-based Protocols for The Treatment of Minor Ailments in Drugstores and Pharmacies in Medellin and The Metropolitan Area, Colombia: A Randomized Clinical Trial PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Minor ailments are common, self-limited conditions unrelated to the patient’s underlying health problems or adverse effects of their current medications. Minor ailment services are pharmacist-led interventions that provide patients with the most appropriate recommendation when unsure about the medication for a specific minor ailment. It involves advice on nonprescription drugs, non-pharmacological measures, or referral to another health care practitioner. In Colombia, evaluating and implementing this service could optimize nonprescription drugs use and improve minor ailment management in primary health care settings. |
PEDRO AMARILES; | 2025-08-29 |
| 144 | Characterization of The IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19 PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Type I interferon (IFN-I) production is triggered by the detection of viral molecules, such as strands of viral RNA or DNA, by receptors known as PRRs (Pattern Recognition Receptors) present on many cell types. These interferons are secreted in minimal concentrations but can activate neighboring cells to secrete over 700 proteins with antiviral properties (inhibition of viral replication, destabilization of viral membranes, etc.). Thus, the IFN-I response serves as the immune system’s first line of defense during a viral infection. Very early in the COVID-19 pandemic, several research teams, including ours, … |
JEAN-CHRISTOPHE RICHARD; | 2025-03-10 |
| 145 | SPOTFIRE ST TITUS STUDY: Provider Identified Target Populations, Implementation, Test Performance, Potential Utility, and Satisfaction of SPOTFIRE ST in The Urgent Care PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate where urgent care (UC) clinicians see the most benefit for a novel, point of care pharyngitis test, SPOTFIRE ST, and describe its performance, potential clinical utility, and satisfaction of providers and patients with this novel test. Up to 200 participants will be on study for up to approximately 25 minutes. |
ALEXANDER LEPAK; | 2026-03-23 |
| 146 | Acceptability, Usability and Preliminary Effectiveness of ChatGPT in Increasing Seasonal Influenza Vaccination Uptake Among Older Adults in Hong Kong PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: In this project, we will train a ChatGPT to provide real-time answers to questions related to the SIV for older adults in Hong Kong. This study aims to evaluate the usability, acceptability, and preliminary effectiveness of the ChatGPT among 50 community-living people aged 65 years and above in Hong Kong. The primary objectives are to evaluate the usability and acceptability (including the extent of usage and subjective experiences of behavioural, cognitive, and affective engagement) of the ChatGPT at the end of the 4-week intervention period (T1). The secondary objectives are to evaluate the following conditions measured at T1, … |
ZIXIN WANG; | 2025-03-31 |
| 147 | A Open-label Phase 2 Study of ZSP1273 in Otherwise Healthy Children 2-17 Years Old With Influenza A PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This trial is conducted in China. The aim of the trial is to investigate safety,pharmacokinetics and pharmacodynamics of ZSP1273 granules |
GUANGDONG RAYNOVENT BIOTECH | 2025-11-17 |
| 148 | A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as flu shot) into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine could improve the immune system response against the cancer. The names of the study drug involved in this study is: -Fluzone Influenza vaccine (flu shot) |
KARAM KHADDOUR; | 2025-10-02 |
| 149 | A Comparative Study on The Immunogenicity and Safety of Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in The Elderly PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: To compare the immunogenicity, cellular immune response, and safety between adjuvanted (aIIV4) and non-adjuvanted (IIV4) seasonal influenza vaccines in the Taiwanese elderly population with chronic medical conditions. |
JANN-TAY WANG; | 2026-02-24 |
| 150 | The Immunogenicity and Safety of COVID-19 and Influenza Vaccine Co-administration and Interval in Immunocompromised Hosts PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this pragmatic embedded open-label, 2 x 2 factorial phase II randomized controlled trial is to evaluate strategies to improve COVID-19 booster and influenza vaccine immunogenicity in people living with immunocompromising conditions (PLIC). The main questions it aims to answer are: 1. Is co-administration of seasonal inactivated influenza vaccine (IIV) with the most up-to-date recommended COVID-19 booster dose non-inferior in inducing a 1-month peak protective humoral response against COVID-19, … |
RUTH SAPIR-PICHHADZE; | 2026-03-10 |
| 151 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess The Safety and Immunogenicity of A Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of A Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Study VBT00001 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of IIV-HD (high-dose inactivated influenza vaccine) + rC19 (adjuvanted recombinant COVID-19 vaccine) vaccine comprised of IIV-HD combined with different recombinant Spike (rS) antigen levels of rC19 compared to IIV-HD alone, rC19 (dose 1) alone, and IIV-HD and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the IIV-HD alone, rC19 (dose 1) alone, … |
SANOFI | 2025-04-01 |
| 152 | A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate The Immunogenicity, Reactogenicity, and Safety of MRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age PF:6 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea). |
MODERNATX | 2025-12-02 |
| 153 | A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess The Safety and Immunogenicity of A Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of A Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alone, and RIV and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the RIV alone, rC19 (dose 1) alone, … |
SANOFI | 2025-05-28 |
| 154 | A Randomized, Partially Blinded, Positively Controlled Phase I Clinical Trial to Evaluate The Safety and Immunogenicity of Lyophilized Haemophilus Influenzae Type B Conjugate Vaccine in A Population Aged 2 Months and Older PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This trial is a randomized, partially blinded, positively controlled phase I clinical study. A total of 160 persons aged 18-59 years, 1-5 years, 6-11 months and 2 months (60-89 days) will be recruited into the trial, and the enrollment will be done according to the progression of age groups, from the oldest to the youngest, and the initial safety assessment will be conducted on the 8th day after the first dose of vaccination for each age group, and the next group will be enrolled only after the safety is confirmed. |
HONGYING LI; | 2025-07-29 |
| 155 | Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Relapsing polychondritis (RP) is a rare, systemic autoimmune disorder characterized by episodic inflammation of cartilaginous structures. The goal of this clinical trial is to learn if drug Upadacitinib works to treat relapsing polychondritis in adults. It will also learn about the safety of drug Upadacitinib. The main questions it aims to answer are: * Does drug Upadacitinib reduce the disease activity of relapsing polychondritis? * What medical problems do participants have when taking drug Upadacitinib? Researchers will compare drug Upadacitinib to conventional therapies (treatment with corticosteroids combined with immunosuppressants) to see if drug Upadacitinib works to treat relapsing polychondritis. Participants will: * Take drug Upadacitinib or corticosteroids combined with immunosuppressants every day for 24 weeks. * Visit the hospital once every month for checkups and tests. This clinical study will explore the efficacy and immunological evaluation of Upadacitinib in the treatment of RP. |
HE JING; | 2025-03-12 |
| 156 | A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF COMBINED VACCINE CANDIDATES AGAINST INFLUENZA AND COVID-19 IN HEALTHY INDIVIDUALS PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study is to learn about flu and COVID vaccines, either alone or when mixed together. Healthy people aged 18 or older can join. Participants will get one shot in each arm, either a flu or COVID vaccine, alone or mixed. The study lasts about 6 months, and participants need to visit the research site at least 3 times. |
BIONTECH SE | 2025-08-15 |
| 157 | ImProving Respiratory Outbreak Mitigation Through Point-of-care Testing in Long Term Care (PROMPT-LTC): A Cluster Randomized Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Outbreaks of seasonal respiratory viruses can spread rapidly in long-term care homes. Timely results for diagnostic tests remains a challenge for respiratory viruses due to the logistics of using a reference laboratory with delays leading to missed opportunities to implement virus-specific control measures to interrupt transmission resulting in larger outbreaks. Use of a point-of-care testing platform is a potential solution that provides faster results, but it is uncertain whether this translates into benefits for long-term care residents. This trial aims to assess whether rapid test results for respiratory pathogens (Influenza, … |
MICHAEL GARRON HOSPITAL | 2025-12-02 |
| 158 | A Phase 3, Randomized, Modified Double-blind, 2-arm Study to Evaluate The Immunogenicity and Safety of High-Dose Inactivated Influenza Vaccine (IIV-HD) Compared With A Standard-dose Inactivated Influenza Vaccine (IIV-SD) in Participants 50 Through 64 Years of Age PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate Immunogenicity and Safety of a High-Dose (HD) Influenza Vaccine (IV) in Adults 50 through 64 Years of Age. |
SANOFI PASTEUR A SANOFI COMPANY | 2025-12-03 |
| 159 | Pilot Sequential Multiple Assignment Randomized Trial for RSV Vaccine Uptake in Pregnancy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Central hypothesis: a multimodal approach is needed to enhance RSV vaccine uptake in pregnancy rather than the current standard of care that relies solely on physician recommendations at routine prenatal visits and/or mass messaging to the public. The investigators propose a pilot sequential multiple assignment randomized trial (SMART) to evaluate the effectiveness of a bundle of evidence-based and sequential strategies to test early (28-30 weeks gestation) and late (34-36 weeks gestation efficacy) to increase RSV vaccination during pregnancy. |
JEANNIE KELLY; | 2025-12-08 |
| 160 | A Phase 3, Randomized, Observer-Blinded, Study to Compare The Safety and Immunogenicity of 3 Lots of Trivalent Hemagglutinin Nanoparticle Influenza Vaccine With Matrix M™ Adjuvant in Participants ≥ 60 Years of Age Related Papers Related Patents Related Grants Related Experts Highlight: Phase 3 Study Comparing Safety and Immune Response of Three Batches of Novavax Flu Vaccine in older adult participants |
NOVAVAX | 2025-03-11 |
| 161 | A Multicenter, Randomized, Double-blind, Positive Controlled Phase Ⅲ Clinical Trial of ZX-7101A Tablets to Evaluate The Safety and Efficacy in The Treatment of Uncomplicated Influenza in Children Aged 5-11 Years PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: A multicenter, randomized, double-blind, positive controlled, phase III trial to evaluate the safety and efficacy of ZX-7101A tablets versus oseltamivir phosphate suspension in children aged ≥5 years and \< 12 years with uncomplicated influenza. |
HANMIN LIU; | 2025-08-13 |
| 162 | A Phase III, Randomized, Open-Label, Active-Controlled Study to Assess The Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Patients 1 to <12 Years of Age With Influenza Symptoms PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety of a single dose baloxavir marboxil compared with 5 days of oseltamivir administered twice a day (BID) in Chinese pediatric participants aged 1 to \< 12 years with influenza symptoms. |
HOFFMANN LA ROCHE | 2025-04-04 |
| 163 | AI-enabled Vaccine Chatbot for Improving Influenza Vaccination Uptake in Children: A Cluster Randomized Trial PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to assess the impact of a vaccine chatbot on improving influenza vaccination uptake among children aged between 6 and 59 months through a cluster randomized trial. Specifically, the main questions it seeks to answer are whether an AI-enabled vaccine chatbot will increase the uptake of influenza vaccine among children and their family members, … |
ZHIYUAN HOU; | 2025-03-31 |
| 164 | Phase Ⅲ, Randomized, Double-blind, Active Controlled to Evaluate The Immunogenicity and Safety of IL-YANG Quadrivalent Seasonal Influenza Vaccine in Healthy Infants From 6 Months to Under 3 Years of Age(≥ 6 Months and < 3 Years) PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG Quadrivalent Seasonal Influenza Vaccine) in healthy infants from 6 months to under 3 years of age(≥ 6 months and \< 3 years) |
IL YANG PHARM | 2026-03-25 |
| 165 | Repeated Cross Sectional Surveillance Study To Determine The Influenza Vaccination Rates in German Participants During Current Respiratory Season PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: Real-time monitoring of vaccination rates for Germany is unavailable, and up-to-date data publication is delayed, which makes it challenging to develop effective public health strategies to increase vaccination coverage. This study aims to address the gap by assessing current influenza vaccination rates, particularly among those aged 60 and older, … |
SANOFI PASTEUR A SANOFI COMPANY | 2026-03-05 |
| 166 | Phase 2a, Single Center, Randomized, Double-blind, Study to Evaluate The Immunogenicity and Safety of One Single Administration of OVX836 Influenza Vaccine at Two Dose Levels (180µg or 480μg) Given Intramuscularly (IM), Either As A Booster or A Primary Vaccination in Healthy Adults Previously Administered With OVX836, Influvac Tetra® or Placebo in The OVX836-002 (EudraCT Number: 2019-002939-28) and OVX836-003 (EudraCT Number: 2021-002535-39) Studies PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This phase 2a is designed to evaluate the anamnestic response of a booster dose (either 180 µg or 480 µg) of OVX836 influenza vaccine administered intramuscularly to participants vaccinated three to five years ago in OVX836-002 or OVX836-003 studies. Participants who had received a placebo or Influvac Tetra® in previous studies would serve as controls and would receive the highest dose of OVX836 vaccine (480 µg) as a primary vaccination. |
OSIVAX | 2025-06-06 |
| 167 | Evaluation of A Multilevel Intervention on Adult COVID-19 and Influenza Vaccination Rate PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: The study will test two tactics to improve uptake of two vaccines in adults. The vaccines prevent COVID-19 and influenza. Both are common and harmful. Most adults do not get either vaccine. This is despite strong recommendations that all adults get both vaccines. The study will involve adult patients at eight Mayo Clinic primary care practices in Rochester and Kasson. The study will test the two tactics together. Four clinics will get the two tactics. The other four clinics will not. The study will randomly assign the two tactics to the clinics. One tactic is to send a letter by US mail to the patient. The letter will state strong recommendations on getting both vaccines now. It will tell patients how to get the vaccines now. The second tactic is to send monthly emails to clinicians. It will remind them to use every visit to vaccinate patients against COVID-19 and influenza. The study will compare the uptake of the two vaccines after six months in the clinics with and without the two tactics. |
LILA J. RUTTEN; | 2025-08-05 |
| 168 | Effect of Influenza Vaccination on Global Systemic Inflammatory Markers in Patients With Stable Coronary Artery Disease – Randomized Delayed-Start Pilot Trial PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Observational and randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Beyond classical view of indirect effect, linked to the neutralisation of the virus, … |
UNIVERSITY HOSPITAL TOURS | 2025-11-21 |
| 169 | Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: The aim of this observational study is to determine if and how kidney failure affects the development of protective immune responses following vaccination in patients on chronic dialysis. Researchers will compare the effectiveness of the influenza vaccine in inducing protective antibodies between hemodialysis patients and subjects without chronic kidney disease. Participants will: * Be enrolled at the time of influenza vaccination * Visit the clinic at 7, 14, 30, 60, and 120 days after vaccination * Be asked to provide relevant clinical information and a blood sample at each visit |
FONDAZIONE IRCCS CA’ GRANDA OSPEDALE MAGGIORE POLICLINICO | 2026-03-30 |
| 170 | Influenza Vaccine Elicited Immune Response in Immunocompromised Patients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to understand how well influenza vaccines work in some individuals with weakened immune systems compared to healthy individuals. Some people, such as those with HIV, multiple sclerosis, certain cancers, or autoimmune conditions, have more severe influenza disease courses due to their medical treatments. These individuals may also respond less effectively to vaccines. By comparing immune responses to the influenza vaccine in both immunocompromised patients and healthy participants, … |
CHRISTINE THURNHEER; | 2025-03-26 |
| 171 | Revealing Protective Immunity to Influenza Using Systems Immunology PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The goals of this study are to better understand the human immune response to influenza vaccines, specifically the live attenuated (weakened) influenza vaccine given as a nasal spray. Better understanding why this vaccine does not work as well in adults as it does in children may help design better influenza vaccines. |
DANIEL S. GRACIAA; | 2026-03-30 |
| 172 | A Single-center, Randomized, Blinded, and Positive Controlled Phase Ⅰ Clinical Trial of The Safety and Preliminary Immunogenicity of Quadrivalent Influenza Vaccine (split Virion) in People Aged 3 Years and Above PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a randomized, blinded, active-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Quadrivalent Influenza Virus Split Vaccine (QIV) in subjects (aged 3 years and above). Primary endpoints are the occurrence of safety events after vaccination including the incidence of adverse events/adverse reactions within 30 minutes/7 days/30 days after immunization, as well as the incidence of serious adverse events/adverse relations within 6 months which will be defined as the secondary safety endpoint. Besides, the secondary immunogenicity endpoints are the geometric mean titers, geometric mean fold increases, seropositive rates, … |
TENG HUANG; | 2025-07-31 |
| 173 | CARE-ID: Dynamics of Respiratory Infections in Children and Transmission in Households and Schools PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Viral respiratory tract infections are very common in children. They contribute to missed time in school, work disruption for caregivers and can also cause severe illness requiring hospitalization and rarely death. In the 2022-2023, influenza, RSV and SARS-CoV-2 viruses infected a large number of children which strained the pediatric healthcare system in many jurisdictions. Unfortunately, there continues to be limited data on duration of infectiousness and transmission risk of these viruses to inform public health decisions during times when there is significant circulation of these viruses. |
MICHELLE SCIENCE; | 2025-11-26 |
| 174 | Text4Vax: Understanding The Effectiveness and Implementation of Text Message Reminders for Pediatric COVID-19 and Influenza Vaccines 2024-2025 Season PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: This multi-site study assesses the impact of text message reminders on the receipt of COVID-19 and influenza text message reminders takes place primarily in practices from the American Academy of Pediatrics (AAP) Pediatric Research in Office Settings (PROS) network. |
MELISSA STOCKWELL; | 2025-07-11 |
| 175 | Double-blind, Randomized, Placebo-controlled, Pilot Clinical Trial to Evaluate The Safety, Tolerability and Efficacy of Two Doses of A Conditioned Medium From A Co-culture of M2-macrophages and Fat-derived Mesenchymal Cells (PRS CK STORM) in The Modulation of The Cytokine Storm for The Treatment of Acute Respiratory Distress Syndrome (ARDS) Caused By SARS-Cov-2, Influenza A, Influenza B and Respiratory Syncytial Virus (RSV) PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this clinical trial is to evaluate the safety, tolerability and efficacy of two doses (dose A and dose B) of Standardized Conditioned Medium Obtained by Coculture of Monocytes and fat-derived Mesenchymal Stromal Cells (PRS CK STORM) in the modulation of the cytokine storm for the treatment of the acute respiratory distress syndrome (ARDS) caused by SARS-Cov-2, influenza A, … |
DAVID BERNAL; | 2025-08-07 |
| 176 | Nationwide Utilization of Danish Government Electronic Letter System for Confirming The Effectiveness of Behavioral Nudges in Increasing InFLUenza Vaccine Uptake Among Adults With Chronic Disease PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: In randomized clinical trials and observational studies, influenza vaccination has been shown to be effective in reducing influenza-related illness, hospitalizations, cardiovascular events, and mortality in select populations. However, the real-world effectiveness of influenza vaccination is limited by its uptake. Conducted during the 2023/2024 influenza season, the first NUDGE-FLU-CHRONIC trial demonstrated the effectiveness of behavioral nudging letters in increasing influenza vaccination rates among adults aged 18-64 years with chronic diseases in Denmark. This present study will once again investigate whether digital behavioral nudges delivered via the official, … |
TOR BIERING-SØRENSEN; | 2025-09-12 |
| 177 | Effectiveness of Local Instillation of Antibiotics Compared to Systemic Antibiotics, As Adjunct to Ultrasound Guided Aspiration in The Management of Breast Abscess; A Randomized Controlled Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Breast abscess, marked by localized collection of pus, frequently follows mastitis. Its prevalence soars up to 16% in the developing world. It usually presents in lactating mothers but also develops in prepubertal females as well. Conventionally it has been treated by surgical incision and drainage with antibiotic coverage, whether oral, intramuscular or intravenous. This approach requires hospital stay and general anesthesia but also have complications like scarring and disfigurement. With the financial and emotional impacts of this technique , … |
ARSLAN ANWAR; | 2025-04-01 |
| 178 | EbolaCov: A Phase IV, Single-centre, Single-blinded, Randomized Controlled Trial to Assess Safety and Immunogenicity of RVSVΔG-ZEBOV-GP Vaccination When Dosed Concurrent With MRNA COVID-19 Vaccine Booster Doses in Healthy African Adults PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Concurrent vaccination scheduling for key target populations in Rwanda, such as healthcare workers, may confer significant advantages in the provision of vaccine coverage to several infectious diseases. This is a phase IV vaccine trial that looks to establish if two licenced vaccines, the rVSVΔG-ZEBOV-GP vaccine for protection against Ebola virus and messenger ribonucleic acid (mRNA) COVID vaccine for protection against SARS-CoV-2 virus, given concurrently to self selected healthy adult volunteers confers an acceptable safety profile and immunogenicity response. |
CHRISTOPHER GREEN; | 2025-05-01 |
| 179 | Randomized, Double-blind, Multicenter, Phase III Clinical Trial Evaluating The Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Clinical trial with an active ingredient of a pharmaceutical specialty marketed in Spain vs. placebo. Randomized, double-blind, multicenter phase III clinical trial that evaluates the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza. |
INSTITUTO DE INVESTIGACIÓN SANITARIA Y BIOMÉDICA DE ALICANTE | 2025-02-19 |
| 180 | A Multicenter, Open-label, Single-arm, Exploratory Clinical Study on The Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension in The Treatment of Uncomplicated Influenza in Pediatric and Adolescent Patients PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study aims to evaluate the tolerability, safety, pharmacokinetic characteristics and efficacy of a single oral dose of GP681 powder for oral suspension in pediatric and adolescent patients with uncomplicated influenza. The study will also explore the optimal dose for a confirmatory clinical trial. Eligible patients who have been confirmed influenza virus infection and have experienced influenza symptoms within 48 hours prior to enrollment, will receive single dose of GP681 powder for oral suspension. The primary outcome measures included the observation of adverse events during the study, the pharmacokinetic parameters, … |
JIANGXI QINGFENG PHARMACEUTICAL | 2025-03-18 |
| 181 | Comparison of High Vs Standard Dose Influenza Vaccines in Pediatric Solid Organ Transplant Recipients PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Influenza virus is a significant pathogen in pediatric solid organ transplant (SOT) recipients. However, these individuals respond poorly to standard-dose (SD) inactivated influenza vaccine (IIV). Recent studies have investigated two strategies to overcome poor immune responses in SOT recipients: (1) administration of high-dose (HD)-IIV compared to SD-IIV and (2) two doses of SD-IIV compared to one dose of SD-IIV in the same influenza season. One study compared HD-IIV vs. SD-IIV in adult SOT recipients and noted that HD-IIV was safe and more immunogenic; however, … |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES NIAID | 2025-03-21 |
| 182 | Comparative Effects of Upper Extremity Proprioceptive Neuromuscular Facilitation and Chest Expansion Exercises on Thoracic Mobility in Children With Cerebral Palsy PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: Thoracic mobility is the mobility of the thoracic spine, and the rib cage is often measured by the degree of thorax expansion during breathing. Thoracic mobility is affected by many reasons, such as breathing mechanics, muscle stiffness, a sedentary lifestyle, … |
NAIMA KHALID; | 2025-01-01 |
| 183 | A Randomized, Controlled, Phase Ⅳ Clinical Trial to Evaluate The Immunogenicity and Safety of Live Attenuated Varicella Vaccine Administered Concomitantly With Trivalent Inactivated Influenza Vaccine (Split Virion) in Children Aged 7-12 Years PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: The goal of this clinical trial is to evaluate the immunogenicity of simultaneous administration of varicella live attenuated vaccine (varicella vaccine hereafter) and trivalent inactivated influenza vaccine (TIV hereafter). It will also evaluate the safety of simultaneous administration of the two vaccines. The main questions it aims to answer are: * If geometric mean titer (GMT) of varicella zoster vrius (VZV) antibody in the simultaneous administration group is non-inferior to that in the varicella vaccine separate group. * If GMT of hemagglutination inhibition (HI hereafter) antibody in the simultaneous administration group is non-inferior to that in the TIV separate group. Participants in the simultaneous administration group received a single dose of varicella vaccine and TIV simultaneously on day 0. Participants in the separate groups received a single dose of varicella vaccine or TIV on day 0, respectively. |
SINOVAC DALIAN VACCINE TECHNOLOGY | 2025-05-23 |
| 184 | The Interaction Between Mucosal Microbiota Colonization in The Nasal Cavity and Gut and The Immune Response to An Intranasal Influenza Live Attenuated Vaccine in Children and Adolescents Aged 6 to 17 Years: A Single-Center, Randomized, Open-Label Trial PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is a single-center, randomized, open-label trial designed to explore the interaction between mucosal microbiota colonization in the nasal cavity and gut and the immune response to an intranasal live attenuated influenza vaccine (LAIV). The study plans to enroll 200 children and adolescents aged 6-17 years, with approximately 50% in the 6-11 years age group and 50% in the 12-17 years age group. Participants and their guardians must be able and willing to comply with the clinical trial protocol and provide informed consent. Eligible participants will be randomly assigned in a 1:1 ratio, stratified by age groups, … |
JING-XIN LI; | 2025-04-24 |
| 185 | A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter Dose Ranging Study to Evaluate Efficacy and Safety of CD388, A Novel Long-acting Antiviral Conjugate, for The Prevention of Influenza in Subjects Not at Risk for Influenza Complications PF:7 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to evaluate the effectiveness of CD388 in preventing symptomatic laboratory-confirmed influenza infections, as compared to placebo, and to select a dose of CD388 that is effective in preventing the same, when administered as a single dose via 3 subcutaneous (SQ) injections to adult participants in stable health, and to evaluate the safety and tolerability of CD388, as compared to placebo. |
CIDARA THERAPEUTICS | 2025-10-20 |
| 186 | Clinical Study on The Immune Response Characteristics of Novel Coronavirus and Influenza Virus Infection PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This is an open-label, prospective observational study in people 18 years of age and older designed to track changes in the dynamics of the respiratory and peripheral blood immune response in people infected with influenza virus and new coronaviruses, and to resolve the characteristics of the virus-induced natural immune response. |
JIANYING HUANG; | 2025-06-30 |
| 187 | A Phase 3, Randomized, Observer-blind, Active-controlled, Case-driven Study to Investigate The Safety, Efficacy, and Immunogenicity of MRNA-1010 Candidate Seasonal Influenza Vaccine Compared With A Licensed Inactivated Seasonal Influenza Vaccine in Adults ≥50 Years of Age PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by any influenza A or B strains. |
MODERNATX | 2025-09-10 |
| 188 | Safety of Simultaneous Versus Sequential Administration of MRNA COVID-19 Vaccine and Inactivated Influenza Vaccine (IIV) in Pregnant Women PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a prospective, randomized clinical trial. During this study, pregnant women will be randomly assigned to receive IIV and mRNA COVID-19 vaccine either simultaneously or sequentially (7-14 days apart). All participants will receive an mRNA COVID-19 vaccine at Visit 1 (Day 1). Solicited local and systemic symptoms of reactogenicity will be assessed on day of visit for Visits 1 and 2 and daily during the 6 days following each visit using either electronic or paper symptoms diaries, … |
GEETA SWAMY; | 2026-01-15 |
| 189 | A Blinded, Randomized, Placebo-Controlled, Influenza Challenge Study in Healthy Adult Volunteers Using A Recombinant H3N2 (A/Texas/71/2017 (H3N2), Clade 3C3a) Influenza Challenge Virus PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: The overall objective of the present study is to utilize the recombinant H3N2 (A/Texas/71/2017 (H3N2, clade 3C3a)) influenza virus for a controlled human infection model to study host responses to influenza virus with the aim of identifying volatile markers in exhaled breath and expression markers in saliva for early detection of infection after pathogen exposure. This study will aim to recruit up to 40 healthy volunteers between ages 18-45 who will receive a single dose of either intranasally administered placebo (sham inoculum) or the virus challenge strain at a concentration known to elicit a \~60-80% attack rate. The response to influenza challenge will be measured by clinical, laboratory, immunological, digital biomarker, on-breath volatile organic compound data and host RNA expression in both blood and saliva. The study will enroll and challenge up to 34 healthy adult volunteers with live virus plus approximately 6 sham-inoculated controls who will be prescreened for study inclusion to have serological antibody titers of ≤1:40 against the challenge strain. Each participant will complete up to 3 weeks of follow-up post confinement. |
DUKE UNIVERSITY | 2025-02-26 |
| 190 | An Exploratory Study to Establish The Dose, Safety and Pathogenicity of A New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: An Exploratory Study to Establish the Dose, Safety and Pathogenicity of a New Influenza A H3N2 Challenge Strain in Healthy Participants 18 to 55 Years of Age In Part A, up to 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2). Based on the outcome of Part A, participants in Part B, may be given Virus Dose 1, Virus Dose 2, or another virus dose (e.g., Virus Dose 3) |
ALEXANDRE LIMA; | 2025-08-22 |
| 191 | Measuring Immunity Against Circulating Influenza Viruses: Randomized Immunogenicity Study Among US Adults Aged 18-64 Years Comparing Two Approved Influenza Vaccines PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: This study is a randomized immunogenicity study in an enrolled cohort with active surveillance for influenza-like illness (ILI). During this study, participants will be randomly assigned to receive an approved cell culture-based influenza vaccine (Flucelvax) versus a licensed comparator influenza vaccine (Flublok or Fluzone). Blood samples from participants will be collected for measurement of biomarkers of immune response at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), and post-season (visit 3; day 181). Participants will be asked if they wish to also provide saliva specimens at baseline (visit 1; day 1), post-vaccination (visit 2; day 29), … |
EMMANUEL B WALTER; | 2025-05-21 |
| 192 | Kaiser Permanente VACCination Improvement With Nudge-based CardiovAscular Targeted Engagement PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: In randomized clinical trials and observational studies, influenza vaccination is effective in reducing influenza-related illness and hospitalizations and potentially cardiovascular (CV) events and mortality in select populations. However, the potential population-level benefit of influenza vaccination is limited by its uptake. Novel implementation strategies to improve vaccination uptake are needed. KP VACCINATE is a multicenter, sequential, individual-level randomized controlled implementation trial examining the effectiveness of a CV-focused nudging communication vs. usual care communication on influenza vaccination uptake among Kaiser Permanente Northern California (KPNC) and Kaiser Permanente Mid Atlantic States (KPMAS) eligible members during the 2024-2025 influenza season. |
ANKEET BHATT; | 2025-05-15 |
| 193 | Influenza Reminder Text-Messaging: A Randomized Quality Improvement Effort to Promote Influenza Vaccine in Pediatric Primary Care PF:10 Related Papers Related Patents Related Grants Related Experts Highlight: Through a large, population-level quality improvement effort within the Children’s Hospital of Philadelphia Care Network, we will evaluate text message reminders on flu vaccination rates for both patients with and without a scheduled well child care visit during flu season. |
BRIAN P. JENSSEN; | 2025-10-01 |
| 194 | A Prospective Randomized Trial of Personalized Nudges to Increase Influenza Vaccinations PF:9 Related Papers Related Patents Related Grants Related Experts Highlight: The purpose of this study is to prospectively test whether personalized, message-based nudges can increase flu vaccination compared with nudges that are not personalized or no nudges. |
CHRISTOPHER F CHABRIS; | 2024-12-01 |
| 195 | Effectiveness of A Sustained-release Ammonium Chloride Formulation in Reducing The Viral Load of Patients With COVID-19 or Influenza PF:2 Related Papers Related Patents Related Grants Related Experts Highlight: This is a prospective, double-blind, randomized, comparative effectiveness pilot study evaluating the effect of a sustained-release ammonium chloride formulation (ACF) on viral load dynamics in adult patients with mild or moderate COVID-19 or seasonal influenza infection. Eligible participants are randomly assigned in a 1:1 ratio to receive either ACF (ammonium chloride with vitamin D) or a control formulation (vitamin D only) twice daily for 10 consecutive days. The primary objective is to assess the reduction of viral load measured by RT-PCR cycle threshold (Ct) values at baseline, Day 3-5, … |
NIKOLAOS DRAKOULIS; | 2025-11-28 |
| 196 | A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study on The Safety and Efficacy of GP681 Tablets in Patients With Influenza at High Risk of Influenza Complications PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications. |
JIANGXI QINGFENG PHARMACEUTICAL | 2025-12-30 |
| 197 | Rapid Molecular Diagnosis and Detection of Emerging Infectious Diseases in Patients With Tropical Fever PF:4 Related Papers Related Patents Related Grants Related Experts Highlight: Travellers returning from tropical countries often present to emergency departments with acute fever. While systematic screening for malaria is well established in clinical practice in France, further diagnostic testing for infectious diseases is less codified. In addition, the clinical presentation of many tropical and emerging infectious diseases is often similar, making a positive diagnosis in these patients challenging. Improving the microbiological diagnostic strategy for febrile travellers is crucial because the lack of an accurate diagnosis in many of these patients prevents the implementation of appropriate diagnostic and therapeutic measures. These measures include antimicrobial treatment, but also additional investigations, … |
ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS | 2025-06-06 |
| 198 | Randomized, Double-Blind, Phase 2 Study to Assess Safety and Immunogenicity of A/H5 Inactivated Monovalent Influenza Vaccines at Different Antigen Dose Levels Adjuvanted With AS03® or MF59® PF:5 Related Papers Related Patents Related Grants Related Experts Highlight: This BARDA-sponsored, randomized, double-blind, phase 2 study is designed to assess safety and immunogenicity of A/H5 inactivated monovalent influenza vaccines at different antigen dose levels adjuvanted with AS03 or MF59. |
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY | 2026-01-09 |
| 199 | Surveillance of Respiratory Viruses in Healthcare and Animal Workers in The Netherlands PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Outbreaks with viruses occur continuously, and novel viruses or new variants of existing viruses can surface after a zoonotic event or human-to-human transmission. This project proposal is designed to detect early circulation of (novel) respiratory viruses in both symptomatic and asymptomatic participants, either by direct detection of the virus or changes in local or systemic immunity. Additionally, SENTINEL will provide information on infectivity and (protective) immune responses in viral outbreaks or vaccination campaigns. |
CORINE GEURTS VAN KESSEL; | 2025-09-05 |
| 200 | A Phase III, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate Pharmacokinetics, Safety and Efficacy of ADC189 Tablets/Granules in Children 2-11 Years Old With Influenza PF:3 Related Papers Related Patents Related Grants Related Experts Highlight: Currently, there is only one treatment which only need one single oral dose for influenza in children five years above (Baloxavir marboxil) in China. This study will test a medicine for influenza in children younger than 5 year of age to see if it is safe and effective. This is a multicenter, randomized, double-blind, controlled Phase III clinical study. The study evaluates the pharmacokinetics, safety and efficacy of ADC189 tablets/granules following a single oral dose in children aged 2 to 11 years with influenza. |
JIAXING ANDICON BIOTECH | 2025-09-23 |